acn

Healthy pipeline, diversification and cost discipline position the Company for long-term growthKey Financial Performance Highlights for the Financial Year (FY2025):- Group’s total revenue for the financial year is RM222.7 million, mainly driven by the e-mobility and energy storage segment, supplemented by the electronics segment.- Recorded LAT of RM40.9 million for Q4FY2025 and LAT of RM27.2 million for the financial year.BANGI, Malaysia, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - Technology leader in providing turnkey, intelligent manufacturing automation solutions, Genetec Technology Berhad (“Genetec” or the “Company”), today announced its financial results for the year ended 30 June 2025 (“FY2025”). The Company reported a gross profit of RM12.7 million for FY2025, supported by continued deliveries in the e-mobility and energy storage segments. The Company recorded a loss after tax (LAT), mainly reflecting higher logistics costs and non-operational, one-off expenses, while underlying fundamentals remain intact.Performance was affected by logistics constrains and one-off costs. Despite this, the Company continued to invest in strengthening its capabilities and supporting future project scopes. Profitability is expected to normalise in FY2026 as markets stabilise and as projects are executed effectively. Genetec is also reinforcing its organisation by bringing in experienced professionals into strategic roles, aimed at broadening capabilities and supporting its long-term diversification strategy.Healthy Orderbook through Diversified MarketsThe Company’s order and tender books remain intact and healthy, underpinned by recurring orders from existing clients as well as new opportunities from a more diversified client base across multiple industries and regions.Deepening Engagement with Existing ClientsAlongside diversification, Genetec continues to strengthen partnerships with its existing clients. Recurring orders and new programme awards reflect the trust and confidence these clients place in Genetec’s execution capabilities and proven track record.Global Manufacturing Trends Creating TailwindsGlobal geopolitical shifts are leading manufacturers across industries to re-evaluate their production footprints and enhance operational resilience. This trend is fuelling greater demand for automation solutions that are flexible, cost-competitive, and consistently high in quality. With its Malaysia-based production model, strong international track record, deep technical know-how, and agile manufacturing capabilities, Genetec is well-positioned to support clients as they navigate and adapt to these evolving requirements.Positive Outlook for BESS PipelinesThe Battery Energy Storage System (BESS) segment continues to gain momentum, with Genetec executing projects across domestic and international markets, and seeing growing local interest in BESS solutions for peak shaving following the recent tariff revision.Chief Executive Officer and Co-founder of Genetec, Chin Kem Weng commented, “FY2025 was a year of investment and transition. We made deliberate strategic choices to strengthen our foundation, safeguard delivery timelines, and support new project scopes. While these factors impacted margins in the short term, they reinforce our capabilities and credibility as a trusted partner. We expect profitability to normalise as market stabilise and as we build on execution experience.”“At the same time, our pipelines remain healthy, supported by recurring orders from existing clients and new opportunities across diversified industries and regions. Our inclusion in both the conventional and Shariah FTSE4Good Bursa Malaysia indices reflects the strength of our governance and sustainability practices. As Genetec approaches our 30th year in business, we remain committed to creating long-term value for clients, shareholders, and stakeholders.”About Genetec Technology BerhadGenetec Technology Berhad is a public listed company on the Main Market of Bursa Malaysia Securities Berhad (Stock code: 0104) and a global leader in providing customised, turnkey smart factory automation solutions. With a strong international footprint, it serves a diverse range of industries including electric vehicle (EV), e-mobility and energy storage, automotive, hard disk drives (HDD), consumer electronics, appliances, and pharmaceuticals.For more information please visit: https://genetec.net/.Issued on behalf of Genetec Technology Berhad by Narro CommunicationsFor media enquiries on Genetec Technology Berhad, please contact:Farah Shahrul                                               Narro Communications                               E: farah@narrocomms.com                           Joyce ShaminiNarro CommunicationsE: joyce@narrocomms.com Copyright 2025 ACN Newswire via SeaPRwire.com.

SHANGHAI, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (the “Company”, HKEx: 2552) announced the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2025 (the “Reporting Period”), as well as the Company's business progress during the first half of the year and future outlook. During the Reporting Period, the commercialization of the Company's core product, HuaTangNing (dorzagliatin tablets), accelerated. The Company’s independent operational capabilities improved significantly. R&D progress advanced smoothly and the Company’s financial performance achieved breakthrough growth, laying a solid foundation for long-term sustainable development.Sales of HuaTangNing increased by 108% year-on-year, with net sales increasing by 112% year-on-year. Reimbursement coverage continued to expand, with a significant increase in prescription volumes across Tier 2 and Tier 3 hospitals, as our comprehensive commercialization strategy achieved significant results.Following the termination of the exclusive promotion service agreement with Bayer, the Company recognized a one-time release of previously deferred income of RMB 1,243.5 million, achieving a profit of RMB 1,183.9 million for the first half of the year. This is the Company's first profit during the performance period.A real-world study (BLOOM) involving 80 centers and 2,000 patients with Type 2 diabetes conducted in China further demonstrated the broad applicability and safety of dorzagliatin.A registration application has been submitted in Hong Kong for Dorzagliatin 75mg (brand name: MYHOMSIS®), aiming to extend its presence across Greater China and Southeast Asia.Gross profit margin improved significantly, as production scale and operational efficiency continued to be optimized.“The first half of 2025 was a critical stage in Hua Medicine’s transformation and development. Following the full takeover of the commercialization of HuaTangNing, the Company achieved double-digit growth in sales and revenue through its independently established sales team, thereby validating the effectiveness of the new business model. We have also submitted a new drug application in Hong Kong, China, laying the foundation for dorzagliatin to expand from China to Southeast Asia and the global market,” said Dr. Li Chen, founder and CEO of Hua Medicin “Dorzagliatin has continued to demonstrate broad therapeutic potential in real-world studies, and new evidence has been found in basic research regarding diabetes remission, cognitive improvement, lipid improvement, and muscle gain, further consolidating Hua Medicine’s global leadership in GKA research and development and treatment. In the future, Hua Medicine will continue to focus on diabetes and the entire field of metabolic diseases, driving innovation through research and development and market expansion to bring the benefits of China's original innovative drugs to more patients worldwide.”   Business Highlights and Operational ProgressCommercialization transformation achieved remarkable results, with doubling of sales and profits.Effective from January 1, 2025, the Company terminated its exclusive promotion service agreement with Bayer and fully took over the commercialization of HuaTangNing (å''å ‚å®'®) in China. During the Reporting Period, with unit prices remaining consistent with the same period in 2024, sales of HuaTangNing reached 1,764,000 packs, a year-on-year increase of 108%. Net sales reached RMB217.4 million, a year-on-year increase of 112%. Leveraging strong commercial execution and continuously improving operational efficiency, the Company is moving toward profitability. Hua Medicine has successfully transitioned to a fully independent commercialization phase, confirming growing market demand and the efficient execution capabilities of its independent sales team.Sales of HuaTangNing continued to benefit from its inclusion in China’s National Reimbursement Drug List (NRDL), which took effect in January 2024. Reimbursement coverage under the NRDL has significantly increased accessibility, especially in Tier 2 and Tier 3 hospitals, and played a critical role in accelerating patient adoption.Due to expanded production scale and improved cost efficiency, the Company's gross profit margin increased to 54.2%, higher than 46.5% in the same period last year.With sales revenue growing 112% year-on-year, the Company's sales expenses during the Reporting Period were RMB64.2 million for the six months ended June 30, 2025, growing only 5% compared to the same period last year. The composition of our selling expenses for the six months ended June 30, 2025 changed significantly from the same period in 2024 due to the Company incurring selling expenses directly as a result of assuming sole commercialization responsibilities for HuaTangNing in China, while no longer owing promotion expenses to the former commercialization partner. These figures also reflect a significant positive trend towards profitability and demonstrate our business strategy of optimizing profitability by controlling commercialization sales expenses of HuaTangNing and maximizing production efficiency, where our selling expenses in the first half of 2025 represent approximately 29.5% of total revenue whereas in the first half of 2024, our selling expenses represented approximately 59.5% of total revenue. After terminating the exclusive promotion service agreement with Bayer, the Company recognized a one-time release of previously deferred income of RMB1,243.5 million and transitioned to self-driven growth. Hua Medicine achieved a pre-tax profit of RMB 1,183.9 million for the first half of the year, marking a key milestone of Hua Medicine towards sustainable profitability.As of June 30, 2025, the cash balance was RMB1,022.8 million, laying a solid foundation for the Company's future R&D and commercialization initiatives.Clinical research continues to deepen, with new evidence supporting treatment potentialHua Medicine is conducting multiple post-marketing studies to evaluate the long-term safety and effectiveness of dorzagliatin across diverse patient populations, both in monotherapy as well as in combination with other popular approved anti-diabetic drugs, such as GLP-1 receptor agonists, insulin, DPP-IV inhibitors and SGLT-2 inhibitors. These studies are generating new clinical insights into glucose control, cognitive outcomes, and potential for diabetes remission.A real-world study (BLOOM) is being conducted in 2,000 patients with Type 2 diabetes across 80 centers in China. BLOOM has already completed one-year follow-up in over 1,000 participants. In the real-world setting, BLOOM further demonstrates the broad applicability and safety of dorzagliatin. Patients receiving dorzagliatin in routine clinical practice present with a heterogeneous mix of comorbidities, including various cardiovascular and renal disorders and are managed with multiple concomitant medications. In addition to metformin, more than 60% of patients concurrently used SGLT-2 inhibitors, insulin, GLP-1 receptor agonists, or DPP-IV inhibitors and other anti-diabetic drugs with dorzagliatin. In monotherapy or in combination with the popular above-mentioned anti-diabetic drugs, dorzagliatin was generally well tolerated, and its safety profile remained consistent with previously established data.Hua Medicine presented new data at the 2025 American Diabetes Association (ADA) conference, reinforcing dorzagliatin’s potential as a disease-modifying therapy. Insights into the novel mechanism of action (MOA) of dorzagliatin as a therapeutic GKA were published in Diabetes.Research and Development Pipeline and Future OutlookThe company filed its application for registration of dorzagliatin 75mg in Hong Kong as MYHOMSIS®, aiming to extend its presence across Greater China and southeast Asia.We are continuing expansion on our product pipeline through development of fixed dose combination of metformin and dorzagliatin for patients who have failed to control blood glucose levels while using high dose metformin (daily dose>1500 mg). In the loose dose combination study-DAWN Trial, dorzagliatin add-on to metformin provided HbA1c reduction of greater than 1% and post meal glucose reduction of greater than 5 mmol/L. These desirable glycemic control levels coupled with a very safe 0.8% hypoglycemic rate would suggest strong potential demand for a branded oral anti-diabetic medication using a convenient fixed dose combination of dorzagliatin and metformin. The Pre-IND submission has been achieved in August 2025, and we are expected to initiate the bioequivalence study in early 2026.We are also advancing the combination of dorzagliatin with GLP-1RA, SGLT-2 inhibitors, insulin and DPP-IV inhibitors through combined effects in collecting real world evidence and proof of concept studies in animal models. The synergy between dorzagliatin with these agents has the potential to expand our indications into other diseases in metabolic disorders, such as obesity and MASH.We continue to enhance our collaborations with leading international research institutions. A Phase I investigator-initiated trial supported by the Group and conducted at the University of Pennsylvania – designed to evaluate the efficacy and safety of dorzagliatin in patients with cystic fibrosis-related diabetes (CFRD) – has received clearance from the U.S. FDA.We will continue our engagement in diabetes prevention, opportunities in metabolic disorder related neurodegeneration disease and eventually find a new way to increase healthy life span and longevity in humans.We continue to invest in digital technology platforms to create synergies across functions and enhance branding opportunities using AI technology.As illustrated in our product pipeline chart, we will continue to advance our R&D efforts for both dorzagliatin and our 2nd generation GKA on our own as well as in collaboration with academic and strategic partners. We are working on the registration of dorzagliatin in Hong Kong and continue to seek partnerships in Southeast Asia and Belt and Road nations. In addition, we will continue our business development efforts on our 2nd generation GKA for the global markets based on the initial success of the Phase 1 single-ascending dose study in the United States and the initiation of our Phase 1 multiple ascending dose study planned for late 2025 or early 2026.Financial SummaryAs of June 30, 2025- Bank balances and cash amounted to approximately RMB 1,022.8 million.- Total revenue was approximately RMB217.4 million, representing a year-on-year increase of 112%. Sales of HuaTangNing (å''å ‚å®'®) reached 1,764,000 packs, representing a year-on-year increase of 108%.- Total gross profit was approximately RMB117.8 million, representing a year-on-year increase of 147%. Gross margin was approximately 54.2%, increased by approximately 7.7 percentage points, as compared with the six months ended June 30, 2024.- Total other income amounted to approximately RMB1,254.6 million , of which Bayer's one-time release of previously deferred income was RMB1,243,5 million.- Total expenditures were approximately RMB187.1 million, of which research and development expenditure was approximately RMB65.8 million.- Profit before tax was approximately RMB1,183.9 million, representing  approximately 932% for the six months ended June 30, 2025Forward-Looking StatementsThis document contains statements regarding Hua Medicine’s future expectations, plans, and prospects for the Company and its products. These forward-looking statements pertain only to events or information as of the date they are made and may change due to future developments. Unless required by law, we are not obligated to update or publicly revise any forward-looking statements or unexpected events after the date of such statements, regardless of new information, future events, or other circumstances. Please read this document carefully and understand that our actual future performance or results may differ materially from expectations due to various risks, uncertainties, or other legal requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestors E-mail: ir@huamedicine.comMedia E-mail: pr@huamedicine.comPress DisclaimerFor accuracy and completeness in context, information related to products marketed in China in this material, especially those identified or required, should comply with documents approved by Chinese regulatory authorities.Additionally, such information should not be interpreted as a recommendation or promotion of any drug or treatment, nor should it replace medical advice from healthcare professionals. For medical-related matters, please consult a healthcare professional. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - Shoucheng Holdings Limited (0697.HK, hereinafter referred to as “Shoucheng Holdings”), Beijing Shoucheng Robotics Technology Industry Co., Ltd. (hereinafter referred to as “Shoucheng Robotics”), IAT Automobile Technology Co., Ltd. (300825.SZ, hereinafter referred to as “IAT”), and Beijing IATROBOT Technology Co., Ltd. (hereinafter referred to as “IATROBOT”) officially signed a strategic cooperation framework agreement.The four parties will leverage their respective strengths to carry out comprehensive cooperation in technological innovation, application deployment, industry chain collaboration, and talent cultivation within the robotics sector, jointly accelerating the development of new business models in the “Robotics + Automobiles” field.I. Industry Background: Robotics Entering the Acceleration Phase of Application DeploymentAt present, the global robotics industry is in a stage of rapid development, with national strategies and policies being introduced intensively. On August 26, the State Council officially released the Opinions of the State Council on Deeply Implementing the “AI+” Initiative (Guo Fa [2025] No. 11), which explicitly calls for promoting the extensive and in-depth integration of artificial intelligence with various industries and fields across the economy and society, and accelerating the formation of new models of intelligent economy and intelligent society characterized by human-machine collaboration, cross-industry integration, and co-creation.Under this national strategy, the robotics industry is shifting from “technological breakthroughs” to “application deployment.” Automobiles and robotics, as two highly complementary industries, are increasingly showing a trend of cross-sector integration. The cooperation between Shoucheng Holdings and IAT Group, under the dual drivers of favorable policy and strong market demand, will inject new momentum into robotics applications across key segments such as R&D, manufacturing, transportation, and mobility services.IAT is a leading enterprise in China’s automotive design field and the only independent automotive design company listed on the A-share market. The company provides full-process services ranging from complete vehicle R&D and design to core component manufacturing, while pursuing a globalization strategy of “technology + supply chain.” According to public information, IAT has served more than 80 clients and participated in the development of nearly 500 vehicle models. Its clients include major OEMs such as FAW, Dongfeng, BAIC, Geely, emerging EV brands, as well as joint-venture automakers. This highlights IAT’s strong OEM resources and delivery capabilities across the automotive value chain.At the same time, through its subsidiary — Beijing IATROBOT Technology Co., Ltd. — IAT has officially entered the robotics sector. IATROBOT is dedicated to building an integrated R&D, design, and simulation training platform, capable of supporting multi-scenario robotics development from simulation and testing to optimization. The company has already launched multiple R&D projects, including wheeled robots, underwater robots, drilling robots, and pet-care robots, demonstrating its potential in cross-scenario development and industry collaboration. The involvement of IATROBOT expands the scope of this cooperation beyond traditional automotive design, providing important support for the integration of robotics R&D, simulation, and automotive industrialization.By partnering with IAT and IATROBOT, Shoucheng will be able to embed robotics technologies deeply into the core stages of the automotive value chain, such as vehicle manufacturing, intelligent assembly, and production line testing. This will enable robots to truly enter the production line and accelerate industrial adoption. This strategic cooperation is not merely a technological connection — it leverages IAT’s extensive OEM client network to move robotics scenarios from “next-door demonstrations” directly into the “factory workshop,” bridging the crucial pathway between R&D validation and scaled industrial delivery.II. Key Areas of Cooperation: Balancing R&D Breakthroughs and Application DeploymentGuided by the State Council’s “AI+” Initiative, the four parties will anchor their collaboration on the full chain of “technology R&D — industrial application — ecosystem co-construction,” working together to drive industrial innovation. The cooperation will focus on the following areas to promote the deep integration of robotics and automobiles:(1) Technological Innovation and Joint R&DThe four parties will jointly build an integrated robotics R&D and simulation platform, drawing on the comprehensive R&D system of the automotive industry. The focus will be on achieving breakthroughs in key areas such as motion control, structural optimization, automotive-grade components, and large-scale manufacturing. Leveraging NVIDIA Isaac/Omniverse technology, the parties will co-develop an integrated simulation training platform that not only supports simulation of robotics applications in automotive R&D, manufacturing, and testing, but also enables cross-scenario simulations such as collaborative operations between autonomous driving vehicles and logistics robots.In addition, a mechanism for data and outcome sharing will be established: Shoucheng Holdings will provide operational data resources from transportation and mobility scenarios, while IAT will contribute expertise in automotive engineering and robotics R&D, together forming a complete closed loop spanning simulation — R&D — validation — production line application.(2) Priority Procurement and Synergy MechanismAcross R&D design, simulation training, complete machine and component supply, the four parties will adopt a priority procurement mechanism, under which signatories will be given preference as partners under equivalent conditions. Shoucheng Holdings and Shoucheng Robotics will focus on product promotion, distribution, and supporting services, while IAT and IATROBOT will concentrate on technology R&D, engineering validation, and customized whole-machine development.The parties will also work together to advance secondary development of robotic systems, ensuring optimal adaptation of robotics products to scenarios such as automotive production lines, intelligent assembly, and line testing. Through division of labor and collaborative mechanisms, a complementary cycle of product supply — technological innovation — application feedback will be established, accelerating the conversion of results and enhancing commercialization efficiency.(3) Talent DevelopmentLeveraging the research and industrial platforms of Shoucheng, IAT, and their partners, the four parties will jointly carry out technological problem-solving, simulation training, and application pilots, providing researchers and engineers with cross-industry, cross-scenario practical environments. Regular technical seminars and industry forums will be held, inviting experts and upstream and downstream enterprises to participate, thereby establishing a joint talent development mechanism. This initiative aims to cultivate a new generation of young researchers with both automotive engineering backgrounds and practical experience in robotics industrialization, laying a solid talent foundation for long-term growth.(4) Expanding Development HorizonsThe four parties will closely align with national strategies for “AI+” and robotics industry development, with a focus on scaling up “Robotics + Automobiles” applications in R&D, manufacturing, testing, and mobility services. Building on this foundation, the cooperation will gradually extend into broader fields such as smart transportation, intelligent manufacturing, healthcare, education, and public services, covering the design, R&D, production, testing, and commercialization of robots and core components. At the same time, by integrating capital and industry, the parties will drive coordinated upgrades across the value chain, ultimately forming a full-cycle closed loop from R&D validation to large-scale application. This will create a demonstrative “Robotics + Automobiles” application matrix, achieving mutual benefits and long-term value creation.III. Strategic Significance: Establishing a New Benchmark for Robotics ApplicationsThe greatest value of the robotics industry lies in real-world applications, and “Robotics + Automobiles” stands out as one of the most promising and high-potential application directions. From complete vehicle R&D to intelligent manufacturing, from traffic scheduling to smart mobility, robots will create tremendous value across the entire automotive value chain.Shoucheng Holdings, leveraging its capital platform, ecosystem resources, and industrial fund advantages, has invested in leading domestic enterprises such as Unitree Robotics, Galbot, Noetix Robotics, Galaxea-AI, and Booster Robotics, equipping it with the capability to integrate frontier technologies. Shoucheng Robotics has established collaborations with hundreds of high-quality upstream and downstream enterprises, making it one of the most comprehensive resource-linking platforms in China. IAT and IATROBOT, in turn, bring mature automotive engineering systems into robotics R&D and industrialization. Together, the combined strengths of both sides will form a complete pathway of “R&D — iteration — application — scale-up.”By joining forces with IAT, Shoucheng will further integrate its scenario resources and industrial ecosystem with IAT’s expertise in vehicle R&D, engineering capabilities, and industrialization experience. Over the next one to two years, the cooperation will focus on the deep integration of “Robotics + Automobiles,” taking the lead in demonstrating large-scale applications across vehicle R&D, production and manufacturing, smart transportation, and mobility services. This will accelerate the transition of robotics from laboratories to industrialization and large-scale deployment, creating a demonstrative “Robotics + Automobiles” application matrix. At the same time, the cooperation will also look to the international market, bringing Chinese solutions to the global stage, fostering new quality productivity, and generating long-term value for shareholders.Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 29, 2025 - (ACN Newswire via SeaPRwire.com) - Tianneng Power International Limited (the “Company”, together with its subsidiaries, collectively referred to as the “Group” or “Tianneng”), (Stock Code: 00819.HK) releases its interim report for the six-month period ended 30 June 2025.In the first half of 2025, adhering to the Group’s vision of Strategic Guidance and Reformation Breakthrough, Tianneng coordinated the three-wheeled strategy of Industry, Technology, and Capital. While solidifying the core competency of the lead-acid battery business, the Group also accelerated the expansion of overseas markets, released the Group’s built-up potential in new-energy battery, deepened the vertical construction of the battery recycle system, and drove the diversification of products and sustainability.Within the reporting period, the Group made a strategic pivot to reduce the trade business, achieved RMB 21.168 billion in revenue for the manufacturing business, which was stable compared to the same period in 2024, accounting for approximately 87.5% of the total revenue within the sector. In terms of the trade business, the Group realized an overall revenue of RMB 30.24 billion, which represented an 89.47% decrease from the same period of 2024. Within The manufacturing sector, the high-end eco-friendly battery business remained stable, providing a resilient financial support for the Group. The emerging businesses experienced significant growth, among which the Li-ion battery business achieved a revenue of RMB 0.501 billion, representing a 174.58% growth from the same period of 2024. Within the reporting period, the Group achieved a gross profit of RMB 2.537 billion, which is stable compared to the same period of 2024. In terms of operating cash flow, the Group achieved RMB 0.891 billion of net inflow, compared to a net outflow of RMB 0.162 billion in the same period of last year. Overall, in the first half of 2025, Tianneng demonstrated strong resilience, developmental momentum, and strategic commitment in a complex external environment.Internationalisation Accelerated, Overseas Expansion Bore FruitsInternational expansion is a vital fulcrum of the Group in strengthening global competitiveness and achieving incremental leaps. In the first half of 2025, the overseas business experienced remarkable growth with continuous positive feedback, achieving a revenue of RMB 0.226 billion, representing a 75.39% growth from the same period of 2024.Within the reporting period, guided by local demands, the Group accelerated its overseas expansion with global industrial resources, and set up operational teams in countries such as Thailand, Vietnam, and Turkey while developing a sales network in major areas including the Asia-Pacific, Europe, North America, the Middle-East and Africa. In addition, the Group’s production base in Vietnam is being constructed in an orderly manner while the capacity of the assembly base is robustly released, laying the groundwork for future developments in the region. The Group has developed customised products based on specific local demands and emphasised building localised operational teams, while advancing its “Overseas Service” strategy, and systematically constructed localised standards. With these developments, the Group was able to optimise its global supply chain and release future growth potentials.Core Business Stable and Resilient, with Promising Growth MomentumWithin the reporting period, the Group pursued a path of “Stability and Growth Duality” under a complex external environment and industrial structure re-balancing. The high-end eco-friendly battery business demonstrated resilience, achieving a revenue of RMB 18.292 billion, providing the vital financial stability for the Group. The high-end eco-friendly batteries are sealed, maintenance-less lead-acid batteries built with the Group’s innovation in design and manufacturing, highly adapting to the demands of the light electric vehicle market, with their cost and performance superiority, are also widely utilised in various fields, including backup power supplies, automobile batteries, and special-purpose industrial power batteries.The Group solidified its competencies in the core business, upgraded its intelligent manufacturing capabilities, improved the operational management system, consolidated its sales network, drove product quality and comprehensive market competitiveness growth, and fortified the resilience of lead-acid batteries in a complex market environment. Within the reporting period, the Group was able to effectively upgrade its manufacturing efficiency and supply-chain resilience through utilising intelligent manufacturing systems and equipment technology upgrades, while demonstrating effective results in cost management. Through the evolution of battery technologies and product upgrades, the Group constructed a differentiated product matrix targeting major fields of usage such as light electric vehicles, data centres, automobile start-stop batteries, and industrial power batteries,driving a service system upgrade with user value at its core, and organically merged the traditional sales network with an innovative digital ecosystem.Solidifying the Diversity of Technological Road-maps and Accelerating New Business Growth In the first half of 2025, the Group committed to the development of new-energy businesses, including Li-ion batteries, solid-state batteries, hydrogen fuel cells, and sodium-ion batteries, and systematically drove innovative breakthroughs, intelligent manufacturing upgrades, user-scenario extensions, and fostered new business growth. The Group’s Li-ion batteries business mainly targets power storage and low-speed power. Within the reporting period, the Group’s power storage and low-speed power business achieved major improvements both in terms of quality and quantity. Specific markets, such as industrial batteries and automobile A/C batteries, also saw improvements in market volume. Overall, the capacity utilisation of the Group’s new-energy business was significantly enhanced, with remarkable improvements in operational efficiency and revenue, RMB 0.501 billion, a 174.58% increase from the same period of 2024.The Group’s solid-state battery also achieved intermittent success within the three dimensions of high energy density, cycle longevity, and high-rate performance. The Group also formed strategic collaborations with industry leaders in the two-wheeled vehicle market and carried out solution testing with partners targeting the low-altitude flying vehicle market. The Group continued its investment in hydrogen fuel-cells with a full-chain R&D system and an expert team, with advanced products, began testing in user-scenarios such as two-wheeled vehicles, public transportation, heavy trucks, and special-purpose machinery, and collaborated with upstream and downstream partners in constructing an application ecosystem. The Group also spearheaded the development and application of sodium-ion battery technology, and conducted experiments for key metrics such as low-temperature and cycle longevity testing for scenarios such as power storage and automobile start-stop battery in a steady manner. Through the multi-roadmap approach, and the “technology breakthrough - user scenario verification - solution delivery” process, the Group’s new-energy business growth is gradually and steadily shifting from individual verification to chain-release, firmly supporting the business momentum.Strengthening the Recycling System and Fortifying Industrial CollaborationThe battery industry is at the core of the Group’s business, which systematically constructed a full-life industry chain of manufacturing, recycling, and reusing, forming a two-railed industry system of lead-acid battery and Li-ion battery, achieving efficient recycling. Within the reporting period, the recycling business of the Group achieved a revenue of RMB 1.8 billion, a 15.82% increase compared to the same period of 2024.As a leader in the recycling industry in China, the Group is continuously building an effective recycling network with front-end reach and back-end efficiency, promoting the efficiency of waste battery recycling empowered by the collaborative effort of businesses at scale, and achieving a top-of-industry recycling ratio of crucial materials. Within the reporting period, the Group continued to enhance the granularity and precision of the recycling process from recycling, processing, and reusing, improve the differentiating system for Li-ion battery recycling, and improve the resource synergies at core regions and user scenarios. Through uninterrupted exploration of technological potential and system performance optimisation, the Group was able to gradually achieve scale advantage and economic value of the recycling system, injecting continuous momentum for the industry.Looking forward, Tianneng will drive industrial upgrades through technological innovation, empower efficient operation through digitisation, rebuild the value-chain system through ecological collaboration, and seek growth through internationalisation. The Group will solidify its competencies in the lead-acid market, accelerate the research, application, and market expansion process of new energy batteries such as Li-ion battery and solid-state battery. The Group will strengthen its capabilities in battery recycling, enhance the collaborative efficiency of industry-chain integration while expediting its expansion into overseas markets and optimising localised operation, from product to service, and develop into a new-energy battery company that is competitive with a global vision. Finally, the Group will promote the convergence between its company values and social values with a growth mindset and build a new paradigm of sustainable and high-quality growth.About Tianneng Power International LimitedTianneng Power International Limited and its subsidiaries (collectively referred to as “Tianneng” or the “Company”), founded in 1986 and headquartered in China, has developed into a leading enterprise in the new energy battery and the light electric vehicle battery industry with a comprehensive manufacturing system and technological advantage. Tianneng was listed on the Main Board of The Stock Exchange of Hong Kong Limited (Stock Code: 00819. HK) in 2007. After nearly four decades of development, Tianneng has established lead-acid batteries as its core business, focusing on the market of motive batteries for light electric vehicles, while expanding its product in automotive start-stop systems, backup power for communication base stations and other diversified scenarios. The Company is also advancing the R&D, production and sales of lithium-ion batteries, hydrogen fuel cells, sodium-ion batteries and solid-state batteries, offering multi-technology battery solutions for special industrial vehicles, energy storage systems and other applications. Additionally, Tianneng strengthens its recycling economy initiatives around its core operations. Through a dual-track system for lead and lithium recycling, the Company achieves efficient resource regeneration and reuse, building a comprehensive ecosystem for the new energy industry. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 29, 2025 - (ACN Newswire via SeaPRwire.com) - Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its interim results for the six months ended 30 June 2025 (the "Reporting Period"). The Group adopted “one horizontal, one vertical” as its core business strategy: horizontally, it extended a lean management system to advance multi-mode collaboration among medical institution alliances; vertically, it focused on specialty-specific innovation in medical diagnostics to fast-track the translation and implementation of new technologies and products. Meanwhile, the Group leveraged AI to enhance the comprehensive solutions for medical institution alliances, promoted the practical application of AI in healthcare scenarios, and continuously strengthened the value of empowering clinical practices, demonstrating strong operational resilience.In the first half of 2025, due to multiple factors, including the centralized drug-procurement program, cost controls of medical insurance, and fierce market competition, the Group’s short-term results did not meet expectations. However, the Group remained committed to product and business model innovation, and further refined the mechanisms and processes of its operational management. By adhering to lean operations, the overall performance has achieved significant improvements. During the Reporting Period, the Group’s gross profit margin reached approximately 34.0%, representing an improvement of approximately 4.4% over the overall gross profit margin for 2024. The net loss amounted to RMB55.4 million, a significant decrease of 56.1% compared to the same period last year. The joint construction business remained the Group’s largest business segment, which recorded the revenue of RMB180.3 million, accounting for 57.6% of the total revenue, increased by approximately 9.6% as compared with the same period last year, achieving significant outcomes in empowering medical alliance clients through in-depth services, paving the way for the Group’s long-term high-quality growth. During the Reporting Period, the Group’s diagnostic testing services recorded revenue of RMB313.2 millionSteadily implementing “one horizontal, one vertical” strategy, with notable achievements in hospital-enterprise partnerships“One horizontal” ——Extending lean management system to deepen diverse forms of collaboration within medical institution alliancesYunkang has been committed to developing an innovative service mode for the joint construction of medical institution alliances featuring “professionalism as the foundation, standardization as the core, digital intelligence as the means, synergization as the goal”. During the Reporting Period, the Group provided nearly 450 alliance clients with multi-scenario solutions tailored to different clinical needs, including AI+ digital intelligence solutions for medical institution alliances, comprehensive collaborations with medical laboratories, solutions for regional/pathology centers and precision medicine center, and specialty-based solutions for alliance development, among other multi-model collaboration services. By leveraging Yunkang’s strengths, the Group assisted healthcare institutions at all levels in enhancing service capabilities and expanding service coverage, established a hierarchical and coordinated healthcare service system, and promoted the development of regional hierarchical diagnosis and treatment services.During the Reporting Period, despite increasingly fierce market competition, the Group maintained solid growth in the joint construction business through continuous deep collaboration with leading hospitals and municipal and county-level hospitals, further consolidating its competitive advantage.“One vertical” ——Joint innovation platform for diagnostic testing serves as strong driver for R&DThe Group has always focused on “clinical needs”, continuously strengthening hospital-enterprise collaboration and pioneering the establishment of a joint innovation platform for diagnostic testing, driving business expansion and product competitiveness. During the Reporting Period, the Group forged joint diagnostic innovation partnerships with dozens of top-tier medical institutions nationwide, delivering a portfolio of testing products addressing multiple infectious syndromes, including respiratory tract infections, central nervous system infections, urinary tract infections, gynecological infections, and tuberculosis, as well as genetic testing products for personalized medication. Collectively, these innovative products have served nearly 300 clients across the country, and achieved sustained growth in testing revenue.During the Reporting Period, Yunkang and Guangdong Provincial People’s Hospital successively launched a series of new panel products covering respiratory tract infections, central nervous system infections, and invasive fungal infections, successfully creating a standardized incubation model for domestic hospital-enterprise research innovation and translation, as well as a “1+N” medical inspection collaboration network. Moreover, throughout the process of scientific and technological innovation, both parties have gained rich clinical experience. With the active involvement and sustained efforts of dozens of domestic diagnostic experts and scholars, they formulated the Expert Consensus on the Application of tNGS for Clinical Standardization, which was published during the Reporting Period in Chinese Journal of Laboratory Medicine, a leading journal in China’s diagnostic field. During the Reporting Period, Yunkang also maintained close collaboration with the First Affiliated Hospital of Guangzhou Medical University, one of China’s top-tier hospitals, and successfully developed a urinary tNGS product, advancing the clinical practice of precision diagnosis and treatment for urinary tract infections. Simultaneously, Yunkang partnered with the First Affiliated Hospital of Jinan University to establish a “university-hospital-enterprise joint innovation platform” and incubated and operated the “innovation project of psychiatric drug genetic testing”, which has successfully yielded genetic testing products for antidepressants, anti-anxiety drugs, and sedative-hypnotics.AI empowers multi-modal solutions for medical institution alliances, improving quality and efficiency to deepen client services  During the Reporting Period, Yunkang fully employed DeepSeek and achieved digital deployment across its platforms. Centered on the core concepts of “AI+” and “precision diagnostics”, Yunkang extensively applied artificial intelligence technology across the multi-technology platforms of its medical laboratories. Taking the in-depth integration of AI technology with Yunkang pathology diagnosis platform as an example, the per-slide efficiency of AI-empowered diagnostic was continuously optimized, achieving simultaneous improvements in intelligence, efficiency, and quality. Moreover, through the deployment of intelligent applications, Yunkang realized smart online customer services and the efficient review of results and reports, which fully streamlined diagnostic service processes and improved experience and satisfaction of its client services. In the process of jointly developing new technologies and products through hospital-enterprise R&D, Yunkang’s AI technology empowered product innovation and R&D across multiple aspects, including bioinformatics analysis, report interpretation, disease risk assessment, and development and translation of novel products, by leveraging the powerful data analysis, modeling, and predictive capabilities of large-scale AI models. This has accelerated the clinical implementation.Notably, Yunkang unveiled its medical AI model “ZhiYun” developed in collaboration with Runda Medical and Huawei, spanning the entire clinical workflow from pre-diagnosis to diagnosis and post-diagnosis. It will provide more efficient and convenient support and experience across all stages of clinical medical services. Meanwhile, Yunkang signed a strategic cooperation agreement with Runda Medical to strengthen in-depth collaboration across the industrial ecosystems in “AI + IVD + healthcare services”, jointly promoting the development and application of large-scale AI models in the medical field, and providing clients with digital-intelligence healthcare solutions. In the future, “ZhiYun”, the medical AI model, will be piloted in Yunkang’s healthcare partners and gradually rolled out nationwide, to improve quality and efficiency of medical institution alliance operations.Future prospects2025 marks the final lap for implementing the 14th Five-Year Plan. China has accelerated the capacity expansion of premium healthcare resources and their extension to lower-tier markets, resulting in a more balanced regional distribution. The country has also expedited the development of medical institution alliances and driven their upgrade from “framework building” to “high-quality operation”. Clinical treatment is also shifting from “broad-spectrum therapies” to “precision medicine”, with the growth potential of the industry continuing to be realized. At the same time, AI technology has continued to empower hierarchical diagnosis and treatment services, and the industry is embracing new growth opportunities.  Looking ahead, Yunkang will continue to keep pace with industry development trends and align with national policies, further strengthening the value of empowering clinical practices, and persistently exploring the “product innovation + business innovation” dual-pronged model to accelerate business development, deeply empower medical testing services, and benefit more residents.Yunkang Group Limited (Stock Code: 2325)Yunkang Group is a leading medical operation service provider in China, which started to provide standardized medical diagnostic services to medical institutions at all levels as early as 2008. Leveraging its own professional diagnostic capabilities and the nationwide service network of integrated healthcare systems, Yunkang has gradually grown to become a medical operation service platform. Meanwhile, Yunkang is a medical operation service provider in China offering a full suite of diagnostic testing services which are diagnostic outsourcing services and diagnostic testing services for medical institution alliances. Yunkang provides diagnostic services through on-site diagnostic centers to collaborative hospitals in the integrated healthcare systems in China and assists them in improving their clinical diagnosis capabilities through co-developing diagnostic centers. As of today, Yunkang has successfully provided professional services to nearly 450 on-site diagnostic centers. As of June 30, 2025, the hospitals we collaborated with were located across 31 provinces and municipalities in China. Copyright 2025 ACN Newswire via SeaPRwire.com.

Toronto, ON, August 28, 2025 - (ACN Newswire via SeaPRwire.com) - Digital Shovel, a leading innovator in crypto mining infrastructure solutions, is thrilled to announce the successful completion of its partnership with IREN (formerly Iris Energy Limited), marked by the delivery of the final batch totaling 493 MW of busway sets, including active units and spares. This milestone, achieved well ahead of schedule, underscores Digital Shovel’s commitment to excellence and reliability in supporting next-generation data center operations.The partnership, formalized in February 2024, saw Digital Shovel supply IREN with almost 500 MW of busways, critical to powering IREN’s expanding data centers, which are optimized for Bitcoin mining and AI cloud services using 100% renewable energy. The project was completed without delays, with deliveries consistently surpassing expectations, enabling IREN to advance its operational timeline.“We are incredibly proud of the seamless execution of this partnership with IREN,” said Scot Johnson, CEO of Digital Shovel. “Delivering all 493 MW of busway sets ahead of schedule is a testament to our team’s dedication and the strength of our innovative solutions. IREN’s vision for sustainable, high-performance data centers aligns perfectly with our mission, and we’re excited about the impact this project will have on their growth.”The early completion of this contract also positions both companies for future collaboration. “This project has been a fantastic opportunity to showcase what we can achieve together,” Johnson added. “We’re eager to explore new ventures with IREN as they continue to lead in renewable energy-powered data centers for Bitcoin mining and AI applications.”The success of this deployment lays the foundation for expanded collaboration as demand for infrastructure solutions continues to surge. With proven capacity to deliver at scale and speed, Digital Shovel is positioned to help power the next generation of energy-efficient data centers across North America.For more information about Digital Shovel and its solutions, please visit www.digitalshovel.com.About Digital ShovelDigital Shovel is a leading vertically integrated HPC, AI and Bitcoin Mining systems manufacturer, building critical elements for datacenter construction. This includes turnkey modular datacenters, as well as infrastructure including switchgear, Smart PDUs, busway systems and more. For more info, visit www.DigitalShovel.com About IRENIREN (NASDAQ: IREN), formerly Iris Energy Limited, is an Australia-based company operating next-generation data centers powered by 100% renewable energy. With facilities optimized for Bitcoin mining, AI cloud services, and other power-dense computing applications, IREN is a global leader in sustainable, high-performance data center solutions. For more information, visit www.iren.com.Media Contact:Press@DigitalShovel.comhttps://www.digitalshovel.com  Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - On August 27, CALB Group Co., Ltd. ("CALB" or "the Company," stock code: 3931.HK) announced its unaudited condensed consolidated interim results for the six months ended 30 June 2025 (the "Reporting Period"). During the Reporting Period, the Company delivered outstanding operational performance with revenue of RMB16,418.88 million, representing an increase of 31.7% compared to the same period last year, and realized a profit of RMB752.99 million, representing a year-on-year increase of 80.4%. In the first half of 2025, the Company showed strong profitability and resilience during the accelerated trend of transformation of global renewable energy development.According to SNE Research, the Company’s installed capacity of globally EV batteries in the first half of 2025 increased 22.7%, ranking third domestically and fourth globally, with the monthly installed capacity reaching 4.7GWh. The Company was particularly outstanding in the domestic passenger vehicle market with the market share hitting new highs in June and July, reaching 7.4% and 8.25%, respectively. In the energy storage sector, the Company's growth was even more rapid. According to InfoLink, the Company’s shipment in the first half of the year ranked fourth globally, achieving milestone development in the energy storage sector.Centered on continuous technological breakthroughs and with the launch of multiple major products, in the first half of 2025, the Company maintained its leadership in cutting-edge battery technology with the “UP” battery. At the same time, the Company’s 400Wh/kg solid-liquid hybrid battery is poised for mass production and commercial deployment, while significant progress has been made in the all-solid-state battery—including breakthroughs in R&D and the commissioning of a dedicated production line. CALB’s high-power lithium iron phosphate R46 large cylindrical battery is the first in the industry to achieve mass production and has successfully achieved mass production for the latest PHEV models from Geely and Dongfeng. At the same time, the Company’s next-generation lithium manganese LFP battery product achieves an energy density exceeding 210Wh/kg and will also go into mass production. With improved performance, the product can attain 10%- 80% charging within 15 minutes.In the passenger vehicle market, leveraging exceptional product capabilities, the Company achieved full entry into the world’s top three automakers, namely Volkswagen, Hyundai and Toyota. In the first half of 2025, its 800V 5C batteries achieved a monthly sales volume of over 20,000 packs, which will support models for XPeng, Ledao, Leapmotor, Audi, BAIC, and others, and the 800V 5C high-voltage NCM battery exclusively supports popular models such as XPeng’s new P7 with ultra-long range, helping XPeng’s new P7 create a new world record of driving 3,971km in 24 hours.In the commercial vehicle market, CALB has established a comprehensive product matrix architecture for “ZHIYUAN” batteries, covering all scenarios, all applications, and all capabilities. In the first half of year, the Company’s domestic commercial vehicle installed capacity has increased by 310% year-on-year. CALB is the first in the industry to launch a million-kilometer customized products for light trucks, significantly improving the quality assurance of battery systems and effectively enhancing product competitiveness in the market. Leveraging the outstanding recognition from the light truck field, the Company has established in-depth collaborations with customers such as Chery, Geely, Ruichi, Foton, Dongfeng, Changan, and King Long. In the heavy truck field, the Company has deeply cultivated the market through the scenario-based power consumption design and has achieved full-spectrum collaboration by partnering with customers such as Sinotruk, XCMG, SANY, Shaanxi Automobile, Jiefang, Dongfeng, Lingong, and Liugong.The Company has made significant breakthroughs in the international market, and its energy storage business achieved rapid growth in the first half of year. The 314Ah second-generation long-cycle energy storage cell can achieve an ultra-long service life of 15,000 cycles and high energy efficiency of over 96%, while achieving zero degradation in the first 1,000 cycles, earning high recognition from customers for both the product and delivery capabilities. In terms of the overseas market, the Company has successfully partnered with the largest power plant projects in Latin America and South Africa, entering the supplier lists of several leading developers and power grid companies. Meanwhile, the Company’s next-generation “ZHIJIU” of 588Ah and 600Ah+ large energy storage cells will scheduled for mass production within the year.In addition, the Company is the first in the industry to pass the eVTOL power battery manufacturing compliance review and supports the development of China’s low-altitude economy market by actively exploring emerging markets. At present, the R46 cylindrical battery cell with an energy density of 310Wh/kg is now in mass production for leading eVTOL customers in the industry. At the same time, CALB signed a deepened strategic cooperation agreement with GOVY, under which the two parties will carry out in-depth collaboration in the eVTOL sector and jointly promote the development of standardized eVTOL energy products.Overall, in the first half of the year, CALB focused on the strategy of consolidating its leadership in products and technologies, while accelerating the globalization of its production capacity layout. At present, its battery Pack plant in Thailand has been put into operation, while construction of the Portugal base officially commenced in the first quarter of 2025. Looking ahead, with the further improvement of industrial chain system, the Company is expected to leverage its cross-domain, cross-scenario dynamic storage product matrix to achieve deep synergy in its dynamic storage business, creating cutting-edge product capabilities across all scenarios. At the same time, the Company will continuously explore emerging markets such as rail transit, mining, low-altitude flight, and humanoid robots by offering high-safety, high-reliability, and high-performance product solutions. Furthermore, CALB will continue to advance the implementation of its “energy+” strategy, further consolidating its leading position in the global new energy industry.About CALBCALB is a new energy enterprise specializing in the research, production, sales, and market application development of lithium batteries, battery management systems, and related integrated products and lithium battery materials. As Battery Expert, we aim to build a comprehensive energy operation system, to provide complete product solutions and full life-cycle management for the new energy application market, represented by power and energy storage.Currently, CALB has completed an all-round layout in domestic by setting up industrial bases in Changzhou, Xiamen, Wuhan, Chengdu, Hefei, Jiangmen and Meishan. Meanwhile, CALB has set up bases in Europe and ASEAN, vigorously expanding the layout all over the world to become a global leading enterprise with large-scale intelligent manufacturing capabilities. Copyright 2025 ACN Newswire via SeaPRwire.com.

ROMEOVILLE, IL, Aug 27, 2025 - (ACN Newswire via SeaPRwire.com) - Formerra, a leader in performance materials distribution, today announced an agreement with Epaflex S.r.l. that designates Formerra Europe as the preferred distributor of Epaflex's thermoplastic polyurethane (TPU) lines in the United Kingdom and Republic of Ireland.The partnership leverages Epaflex's 30-year legacy of innovation in TPU manufacturing with Formerra's deep expertise in UK/EU REACH compliance, local technical support, and agile logistics. Additionally, the collaboration ensures that process engineers and sourcing managers across cable, wire, industrial, automation, and oil & gas markets gain seamless access to high-performance TPU grades backed by responsive service and regulatory guidance."We're proud to welcome Epaflex's industry-leading TPU portfolio into our specialist distribution network," said Ronan Kennedy, Managing Director at Formerra Europe. "This agreement opens a true window of opportunity for UK & Ireland processors by delivering advanced TPUs via the reliable supply chains and technical support our customers need."Epaflex is renowned for its Epamould, Epaline, and Epamet engineered TPU formulations featuring high-abrasion, oil-resistance, specialty matte finishes, and low-temperature flexibility. These materials serve critical applications such as cable jacketing, hydraulic hoses, precision tubing, and protective film. Combined with the company's new Epalite material, this portfolio brings durability, processability, and design versatility for today's demanding industrial environments."Partnering with Formerra marks a significant milestone in our UK and Ireland expansion," said Andrea Martignoni, Global Strategic Marketing Manager - Elastomers at Epaflex. "Their local market expertise and commitment to engineer-led service make them the ideal partner to bring Epaflex innovation to manufacturers in this key area of Europe."With this agreement, Formerra further strengthens its European presence, offering unmatched portfolio depth, compliance guidance, and rapid responsiveness to support customers' most challenging TPU applications.Key Details:Formerra Europe appointed preferred distributor for Epaflex TPU lines (Epamould, Epaline, Epamet, and Epalite) in the UK & Ireland.Partnership combines Italian-engineered TPU grades with Formerra's UK/EU REACH expertise and agile service.Target applications include cable/wire jacketing, hydraulic hoses, precision tubing and protective films.About FormerraFormerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways - driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.About EpaflexEpaflex S.r.l., headquartered in Italy, is a leading manufacturer of thermoplastic polyurethanes. For over 30 years, Epaflex has developed innovative TPU solutions for industries including cable & wire, automotive, oil & gas and consumer goods. Its portfolio features high-performance grades engineered for abrasion resistance, flexibility, weather-ability and specialty surface finishes. Privately held under the Elachem Group, Epaflex operates global sales and technical support hubs to serve OEMs and processors worldwide.Media ContactJackie MorrisMarketing Communications Manager, Formerrajackie.morris@formerra.com+1 630-972-3144SOURCE: Formerra Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 26, 2025 - (ACN Newswire via SeaPRwire.com) - Global leading storage battery company in data center and telecom industries – Shuangdeng Group Co., Ltd. (stock code: 06960.HK), today listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”).Shuangdeng Group offered a total of 58,557,000 H Shares in the global offering. The offer price was determined at HK$14.51 per offer share. The net proceeds from the Global Offering are estimated to be approximately HK$756.3 million.The Company intends to use the net proceeds for the following purposes: (1) Construct a lithium-ion batteries production facility in Southeast Asia, which will primarily be used for producing batteries for data centers. (2) Establish a research and development center focusing on the research and development of: (i) enhanced energy storage battery life; (ii) solid state battery; (iii) sodium-ion battery; and (iv) BMS technology. (3) Strengthen overseas sales and marketing so that the Company can enhance its global presence, better serve overseas customers and boost international sales, etc.Shuangdeng Group’s Hong Kong Offering was over-subscribed by approximately 3875.25 times of the 5,856,000 H shares offered. The International Offering also recorded an over-subscription, of approximately 17.75 times of the 52,701,000 H shares offered.The opening price of Shuangdeng Group today was HK$22.50, up by 55.1%, with a total market capitalization of HK$9.38 billion accordingly.Listing CeremonyVIP GroupDr. Yang Rui, Chairman of the Board, Executive Director and Chief Executive Officer of Shuangdeng Group said, “Shuangdeng is not only a provider of energy storage battery products and system solutions but also aspires to be an architect of the AIDC intelligent computing center energy ecosystem, as the ‘Energy Operating System’ of digital infrastructure. We firmly believe that without stable energy supply, there can be no reliable intelligent computing power. We look forward to working with global investors to jointly chart the grand blueprint of a ‘Zero-Carbon Computing Planet.’ Let every watt of energy illuminate the path forward for human civilization!”Dr. Yang Rui, Chairman of the Board, Executive Director and Chief Executive Officerof Shuangdeng Group Co., Ltd. Delivered a SpeechShuangdeng Group is a leading company in energy storage business for big-data and telecommunication industries. Its products span diverse application scenarios, including energy storage for telecom base stations, data centers, and the electrical energy storage settings. According to Frost & Sullivan, in 2024, the Company ranked the first among global telecom base station and data center energy storage battery providers in terms of shipment volume, achieving a market share of 11.1%.With over a decade of dedicated industry expertise, Shuangdeng Group has established a globally leading customer base and brand strength. The Company serves nearly 30 of the world’s top 100 telecom operators and equipment manufacturers, forging strong relationship with leading telecom operators and telecommunication equipment manufacturers in China, such as China Mobile, China Telecom, China Unicom, and China Tower, as well as prominent international telecommunication giants like Ericsson, Vodafone, Orange, and Telenor. In addition, as of December 31, 2024, Shuangdeng Group served 80% of top 10 Chinese self-owned data center companies and 90% of top 10 Chinese third-party data center companies.Capturing the AIDC Opportunity: Data Center Business BoomsAs the key carriers of latest-generation digital technologies, such as artificial intelligence and cloud computing, data centers experienced a rapid growth in recent years around the world. The advent of the AI era is also accelerating the industry trend towards large-scale and high-computing power data centers. According to Frost & Sullivan, the proportion of global electricity consumption by data centers is expected to increase from 4.0% in 2024 to 10.1% in 2030. The dependency of AI and big data on constant power supplies makes energy storage a critical component in the infrastructure supporting these technologies.In 2018, Shuangdeng Group keenly identified the market demands of the internet era and began establishing cooperation relationship with large tech companies and data center operators. Up to August 8, 2025, its energy storage products have been used in hundreds of data centers. According to Frost & Sullivan, in 2024, Shuangdeng Group ranked first among Chinese companies in terms of shipment volumes in the global data center energy storage market, with 16.1% market share in the global data center market.Shuangdeng Group’s batteries applied in data centers, utilizing advanced technologies such as continuous grid plate preparation technology, deliver superior high-rate performance. These products achieve discharge rates exceeding 6C, with instantaneous discharge capabilities reaching 10C, making them ideal products to serve customer-specific performance needs across various application scenarios. Additionally, the Company is leading the development of the industry standard for ‘‘Lithium-iron Phosphate Battery Packs for AC UPS in Data Centers’’ in China, setting the benchmark for energy storage battery technology in the era of big data.According to the prospectus, Shuangdeng Group’s revenues from sales of batteries used in data centers increased by 120% from RMB397.0 million in the five months ended May 31, 2024 to RMB872.9 million in the five months ended May 31, 2025. The contribution of this business segment to total revenue grew from ‌28.4%‌ to ‌46.7%, making it the company’s largest revenue source.In the era of artificial intelligence and big data, Shuangdeng Group is well-positioned to capture the vast market opportunities of the future. Approximately 40.0% of the net proceeds from this IPO will be used for the construction of a lithium-ion batteries production facility in Southeast Asia, which will primarily be used for producing batteries for data centers in order to cultivate its second growth pillar and increase its markets share regarding energy storage products for data centers.‌Strong R&D Drives Innovation, Diverse Products Meet Varied NeedsAs a global leading energy storage battery manufacturer, Shuangdeng Group relies on its in-house R&D to establish and strengthen market position, and achieve continuous growth. The Company has R&D centers located in Taizhou, Shenzhen, Beijing and Xiangyang. These R&D centers focus on the research and development of energy storage battery technologies to improve the safety, cost-efficiency and performance of energy storage batteries. Adhering to the principle of “researching one generation ahead, pilot testing the next, and mass-producing the current”, Shuangdeng Group aims to enhance the market competitiveness of both lithium-ion batteries and lead-acid batteries through its R&D efforts. As of August 8, 2025, the Company held a total of 353 patents, including 111 invention patents.Shuangdeng Group’s technical team has actively participated in the formulation of national and industry-related standards on multiple occasions, demonstrating its strong technological credibility and influence in the industry. As of May 31, 2025, the Company has participated in the formulation of one international standard issued by International Electrotechnical Commission (IEC), 10 national standards and 21 industry standards issued by the Ministry of Industry and Information Technology of the People’s Republic of China and the Standardization Administration of China.In addition, Shuangdeng Group actively pursues collaborative R&D partnerships with external entities to co-develop innovative technologies and products that align with dynamic market needs. The Company works closely with leading experts in the energy storage industry and have formed an external technical expert committee, which was led by academician from the Chinese Academy of Engineering and Chinese Academy of Sciences, and jointed by more than 30 industrial experts to support and advise on technical innovation. The Company has also established profound partnerships with leading universities, research institutions and industry experts. These collaborations have facilitated a series of projects focused on pioneering new technologies, offering crucial technical insights that underpin its future product development strategies.Shuangdeng Group offers a diverse range of products across multiple technology pathways to provide the most cost-effective options that meet customer performance requirements. Apart from lead-acid batteries and lithium-ion batteries, the Company’s sodium-ion batteries have been widely adopted in telecom base stations by telecommunication companies in multiple provinces and regions, including Anhui, Qinghai, Tibet and Gansu. In addition, to further enhance the energy safety, the Company has been actively developing the solid-state battery technology. The joint R&D project with Tianmu Lake Institute of Advanced Energy Storage Technologies has completed development of the key materials, and achieved the fabrication of 100Ah solid-state lithium-ion batteries, which laid a solid foundation for the Company’s future R&D on the technology and manufacture of solid-state battery.For further information, please contact:Porda Havas International Finance Communications GroupKelly Fung +852 3150 6763 kelly.fung@h-advisors.globalMay Yang +86 15021840493 may.yang@h-advisors.global Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 27, 2025 - (ACN Newswire via SeaPRwire.com) - On August 26, CaoCao Inc. (‘CaoCao’ or ‘Company’, Stock Code: 02643.HK) announced interim results. For the six months ended June 30, 2025, CaoCao Inc. operated in 163 cities. Company’s total order volume reached 379.5 million, representing an increase of 49.0% in the same period of last year. During the reporting period, the Company’s revenues increased by 53.5% to RMB 9.5 billion.The announcement shows that the Company’s gross profit margin raised from 7.0% in in the six months ended June 30, 2024 to 8.4% in the six months ended June 30, 2025., while losses narrowed by 39.8% year-on-year. Net cash generated from operating activities increased by 164.6% year-on-year, reflecting an improved financial position.CaoCao Inc. was founded in 2015, incubated by Geely Holding Group. According to Frost & Sullivan, CaoCao Inc. was the second largest ride hailing platform in China in terms of GTV in 2024.The Company has placed and expect to place greater strategic focus on purpose-built vehicles. As of June 30, 2025, it deployed a fleet of over 37 thousand purpose-built vehicles across 31 cities and and CaoCao also collaborated with local car partners through selling them our purpose-built vehicles. For the six months ended June 30, 2025, the GTV contributed by purpose-built vehicles amounted to RMB2.5 billion, reflecting an increase of 34.7% compared with the same period last year.The purpose-built vehicles specifically designed for shared mobility have significantly enhanced the driver and passenger experience. In the first half of the year, CaoCao Inc. saw a year-on-year increase of 57.4% in average monthly active users and 53.5% in average monthly active drivers, with the average order value (AOV) rising to RMB 28.9. In seven user surveys conducted between Q4 2023 and Q2 2025, CaoCao Mobility ranked in user recognition for “best service quality” among China’s leading shared mobility platforms.The company continues to invest in CaoCao Smart Mobility, their autonomous driving platform, to enhance our Robotaxi operation capabilities.Since April 2025, the company has been deploying their latest generation of Robotaxi, which features Geely’s latest redundant architecture design and deeply integrates CaoCao Smart Mobility’s capabilities in automated dispatching, remote safety assurance, travel cabin services, and asset digital management into a unified autonomous driving operation platform. The Company also collaborates with Geely and business partners to develop autonomous driving technology and to pre-install proprietary autonomous driving components and related applications in purpose-built vehicles. By the end of the reporting period, CaoCao Smart Mobility had accumulated over 15,000 kilometers of autonomous driving test mileage in Suzhou and Hangzhou. In addition, CaoCao Inc. continues to promote accessible mobility. On March 28, it officially launched their public welfare brand for accessibility, deploying over 1,000 accessible vehicles across 20+ major cities and holding a monthly “Accessibility Public Welfare Day” to provide free wheelchair-accessible travel for wheelchair users. At the same time, CaoCao Inc. is the first platform in the industry to participate in the pilot program for occupational injury protection for workers in new forms of employment, and has established support initiatives such as the Driver Care Fund and the Driver Children’s Education Fund.Looking ahead, CaoCao Inc. will leverage on competitive strengths, geographical expansion successes, tremendous momentum in Robotaxi development and strategic relationship with Geely Group, the company will continue to optimize their growth strategy, aiming to achieve a healthy combination of fast growth and profitability. Copyright 2025 ACN Newswire via SeaPRwire.com.

Financial HighlightsRMB millionFor the 6 months ended 30 JuneChange 20252024 Revenue76,09079,115(3.82%) Operating Profit2,8172,11533.15% Profit Before Income Tax2,7982,21626.27% Gross Proft9,6438,48613.63% Gross Profit Margin12.67%10.73%1.94% Net Profit1,7641,39526.45% Net profit attributable to shareholders and other equity holders of the Company1,27886647.63% Net profit attributable to shareholders and other equity holders of the Company after deducting non-recurring profit or loss  1,240  82051.18% Net cash flows from operating activities7,154(1,447)594.46%  Results Highlights 01. Energy-related businesses significantly improved profitability, with combined net profit increasing by RMB724 million year-on-year (“YoY”): The offshore engineering segment and the finance and asset management segment (primarily drilling rig leasing) together improved by approximately RMB506 million, and the energy, chemical & liquid food equipment segment improved by RMB218 million. Specifically, the gross profit margin of the offshore engineering segment increased by 5.85 percentage points YoY to 10.84% in 1H 2025, with net profit reaching RMB281 million and a net profit margin of approximately 3.5%. The total order backlog amounted to approximately RMB70 billion, covering periods up to 2027/2028.02. Logistics-related business portfolio mitigated cycles and achieved steady growth: Container manufacturing and sales remained within the prosperous zone, benefiting from the resilience of global trade and the increased penetration of domestic multimodal transport. Sales of new standard dry containers reached 1,125,900 TEUs and refrigerated container sales doubled to 92,000 TEUs. Container manufacturing, airport facilities, and logistics services achieved growth, while the road transportation vehicles business declined. The combined net profit increased by approximately RMB76 million. 03. Significant optimization of interest expenses: The interest-bearing debt balance at mid-year was RMB41.2 billion, a decrease of RMB5.1 billion compared to the same period last year. Benefiting from the active replacement of high-interest floating-rate US dollar bonds in 2024, net interest expenses for 1H 2025 decreased by approximately RMB310 million YoY. 04. Significant improvement in cash flow: Net cash flows from operating activities increased significantly by 594.46% YoY. As of June 2025, net cash flows from operating activities were RMB7.154 billion. HONG KONG, Aug 27, 2025 - (ACN Newswire via SeaPRwire.com) - China International Marine Containers (Group) Co., Ltd. (“CIMC Group” or the “Group”, stock code: 000039.SZ/02039.HK) is pleased to announce the unaudited interim results for the six months ended 30 June, 2025 (the “Reporting Period”).The management of CIMC Group stated: “In 1H 2025, facing impacts such as slowing global economic growth and tariffs, global goods trade demonstrated certain resilience. Benefiting from the diversified business portfolio structure of logistics equipment and services, the enhanced profitability of previously cultivated high-end energy manufacturing businesses, and the continuously optimized debt structure, while the Group, through its continuously consolidated global operation platform foundation during the Reporting Period, smoothed out fluctuations in single regions and achieved stable and quality development. In the first half, the Group achieved revenue of RMB76.1 billion, a decrease of 3.82% YoY; the gross profit margin increased by 1.94% YoY to 12.67%; and net profit attributable to shareholders was approximately RMB1.28 billion, an increase of 47.63%. During the Reporting Period, the Group maintained its global leading position in the production of standard dry containers, refrigerated containers, and special-purpose containers. Revenue from road transportation vehicles, energy/chemical/liquid food equipment, logistics services, and offshore engineering businesses also grew steadily, maintaining overall operational stability. The Group’s domestic revenue accounted for approximately 51%, and overseas revenue accounted for approximately 49%, maintaining a sound market landscape.”Segments Results (RMB million)1H2025 Business indicatorsRevenueAs % of the total revenueGross profitAs % of the gross profitGross profit marginNet profitContainer manufacturing21,73528.57%3,51036.40%16.15%1,444Road transportation vehicles9,75312.82%1,46415.19%15.01%408Energy, chemical, and liquid food equipment13,00917.10%1,96720.40%15.12%460Offshore Engineering8,01410.53%8699.01%10.84%281Airport Facilities and Logistics Equipment, Fire Safety and Rescue Equipment3,1204.10%6426.65%20.56%80Logistics services13,57917.85%8118.41%5.97%202The above major segments69,20991.0%9,26396.06%13.38%2,875Core Business PerformanceI. In the Logistics FieldContainer Manufacturing Business: During the Reporting Period, China’s container supply chain prosperity index remained within the prosperous zone, highlighting the resilience of global goods trade. According to the United Nations Conference on Trade and Development (UNCTAD), global trade volume is estimated to expand by US$300 billion year-on-year in the first half of 2025, with US$230 billion contributed by growth in goods trade. Meanwhile, long-term factors such as Red Sea detours, congestion at Eurasian ports, and stricter regulations on shipping carbon emissions reduced container shipping efficiency, keeping container demand at conventional levels. During the Reporting Period, the Group’s sales volume of dry containers decreased by 18.57% year-on-year to 1,125,900 TEUs (same period last year: 1,382,700 TEUs), mainly affected by the high base in the same period last year; sales of refrigerated containers benefited from strong South American fruit exports and cold chain demand, surging by 105.82% year-on-year to 92,000 TEUs (same period last year: 44,700 TEUs). During the Reporting Period, revenue reached RMB21.735 billion, net profit was RMB1.444 billion, and the gross profit margin increased by 3.95 percentage points YoY to 16.15%.Logistics Services Business: During the Reporting Period, the international trade environment was complex and volatile, and container shipping volume and freight rates fluctuated. However, the accelerated pace of Chinese companies going global drove growth in demand for comprehensive logistics, further highlighting the hub value of logistics service providers in the supply chain. Against this backdrop, the Group’s logistics services business firmly adhered to the development strategy of “high quality, high efficiency, and new momentum,” achieving overall operational stability by optimizing customer structure, innovating business models, strengthening risk management, and improving operational efficiency. During the Reporting Period, the Group’s logistics services business achieved revenue of RMB13.579 billion, a decrease of 3.62% YoY; net profit was RMB202 million, basically flat YoY. Meanwhile, the Group’s ocean shipping division continued to enrich its route offerings and further expanded its global agency network. Despite market fluctuations, it exceeded target cargo volumes on designated routes and was once again listed in the 2025 Top 50 Ocean Freight Forwarders chart issued by the global logistics industry authoritative magazine Transport Topic.Road Transportation Vehicles Business: During the Reporting Period, CIMC Vehicles achieved revenue of RMB9.753 billion (same period last year: RMB10.700 billion), a decrease of 8.85% YoY; net profit was RMB408 million (same period last year: RMB574 million), a decrease of 28.89% YoY. Among these, the new energy heavy-duty truck market continued its explosive growth trend, and the semi-trailer industry in Global South markets showed a pattern of differentiated growth alongside transformation. In the domestic market, the “StarLink Project” and the “Rise-Up Project” achieved results, driving high-quality growth and development of the domestic business. During the Reporting Period, revenue, gross profit margin, and sales volume in China’s semi-trailer market increased by 11%, 2.4 percentage points, and 10% YoY, respectively. Its market share in China’s semi-trailer market rose to 23.07%, ranking first in China for the sixth consecutive year. In overseas markets, the semi-trailer business in the Global South continued its high-quality development trend, with the gross profit margin increasing by 4.6 percentage points YoY and sales volume increasing by 13.0% YOY, showing strong profitability growth. Efforts in the new energy sector continued, with sales volumes of EV-DTB dump trucks, mixer trucks, and refrigerated trucks increasing by 142.55%, 86.26%, and 69.8% YoY, respectively. The top-level architecture for the pure electric tractor and trailer product EV-RT 2.0 was completed.Airport Facilities & Logistics Equipment / Fire Safety & Rescue Equipment Business: During the Reporting Period, primarily due to the release and settlement of high-quality orders from the previous period during the Reporting Period, the Company proactively optimized the delivery pace and successfully delivered projects such as boarding bridges for the new terminals at Xi’an Xianyang International Airport and Antalya Airport in Turkey ahead of schedule. Revenue for the Reporting Period was RMB3120 million (same period last year: RMB2403 million), an increase of 29.83% year-on-year; net profit was RMB80 million (same period last year: RMB 37 million), an increase of 119.57% YoY. During the Reporting Period, the intelligent unmanned docking system (the first batch in the world) was successfully put into operation at Lanzhou Airport, with all 86 boarding bridges at the airport achieving unmanned operation; the overseas Ziegler business saw significant improvements in bid-winning rates, on-time delivery rates, and cost management. CIMC TianDa provided automated delivery and sorting systems to customers in the e-commerce express delivery industry, while actively expanding into diversified niche areas such as pharmaceuticals and textiles. Leveraging the product advantage of cost reduction and efficiency improvement, new orders grew steadily.II. In the Energy Industries FieldIn the energy, chemical, and liquid food equipment business, this segment achieved revenue of RMB13.009 billion (same period last year: RMB12.121 billion), an increase of 7.32% YoY; net profit was RMB460 million (same period last year: RMB242 million), an increase of 90.26% YoY. Among these, CIMC Enric achieved revenue of RMB12.610 billion (same period last year: RMB11.480 billion), a YoY increase of 9.9%; net profit attributable to the Company was RMB560 million (same period last year: RMB490 million), a significant YoY increase of 15.6%; newly signed orders amounted to RMB10.740 billion, and the order backlog as of the end of June was RMB29.180 billion. Specifically, the clean energy segment's revenue grew steadily; demand for LNG refueling stations, LNG tankers, and related equipment continued to increase; the Linggang-CIMC project was successfully constructed and delivered; in the offshore clean energy sector, 9 vessels were delivered, 7 newbuilds were signed, and multiple orders for LNG and methanol power packages were secured; in the hydrogen business, bids were won for several green hydrogen ammonia projects domestically and internationally, and multiple orders were delivered to European customers during the Reporting Period; the chemical and environment segment saw a slowdown in demand for tank containers, while the medical equipment components business grew steadily and the after-market business progressed; the liquid food segment’s net profit increased YoY; the new plant in Mexico was fully operational during the Reporting Period, and the first large-scale storage tank project was secured.In the offshore engineering business, in 1H 2025, crude oil prices experienced significant volatility due to uncertainties in U.S. trade policies and geopolitical tensions stemming from the Iran-Israel and Russia-Ukraine conflicts. However, as existing oil fields gradually deplete, the demand for new oil and gas resources is becoming increasingly urgent. The economic value of deep-sea oil and gas development continues to grow, and offshore deep-sea oil and gas production continues to increase. In particular, large-scale floating production equipment, centered around FPSO/FLNG, remains in high demand. During the Reporting Period, the Group’s offshore engineering business recorded revenue of RMB8014 million (same period last year: RMB7784 million), a YoY increase of 2.95%; the gross profit margin increased by 5.85 percentage points YoY to 10.84%; net profit was RMB281 million (same period last year: net loss of RMB84 million), turning a loss into a profit YoY. Among these, the core operating entity, Yantai CIMC Raffles Marine Technology Group Co., Ltd., achieved a net profit of RMB525 million, and the net profit margin increased to 6.56%. As of the end of June, orders newly signed/won amounted to USD 106 million (same period last year: USD 1,790 million), primarily affected by delayed order finalizations. The cumulative order backlog was USD5,550 million. Among these, the proportion of oil and gas orders and non-oil and gas orders was approximately 7:3, effectively easing the periodic fluctuation of the oil and gas market.In the offshore engineering asset operation business, affected by factors such as the impact of U.S. “reciprocal tariffs” on global demand expectations, the greater-than-expected production increase by “OPEC+”, and the unwinding of geopolitical risk premiums, international oil companies shifted their strategic focus back to their core oil and gas business and became more prudent with their investment in low-carbon transformation. The global utilization rate of jack-up platforms declined significantly, and daily rates were under downward pressure. For mid-deepwater semi-submersible platforms, demand for projects in the North Sea and Barents Sea remained stable, while issues related to European energy security supported a steady rise in both utilization rates and daily rates. For ultra-deepwater semi-submersible platforms, certain deepwater development projects were delayed due to adjustments in investment priorities, resulting in a slight decline in the utilization rate compared to the beginning of the year. During the Reporting Period, the Group’s mid-deepwater semi-submersible platform “Deepsea Yantai” secured a new lease agreement with a Norwegian oil company; the ultra-deepwater semi-submersible drilling platform “Blue Whale No. 1” signed a new lease agreement with an international client.Future Development and ProspectsThe Group's Management stated: "CIMC will base itself on the new development stage, closely follow national policy guidance, deepen the implementation of the strategic theme of ‘accelerating the construction of new growth drivers and focusing on promoting high-quality development’, coordinate the reasonable growth of ‘quantity’ and the effective improvement of ‘quality’, and strive to ‘become a high-quality and respected world-class enterprise’."I. In the Logistics FieldIn the container manufacturing business, according to the report issued by CLARKSONS in June 2025, global container trade volume is expected to see a growth of 2.5% in 2025. The uncertainty surrounding U.S. tariff policies will continue to fuel concerns about global economic growth, which in turn will impact the demand for containers in the global container shipping market in the short term. However, owing to the demand for spare containers brought about by these uncertain events in the container transportation market and the stable replacement rate of old containers, the demand for new containers is still expected to be underpinned by stable fundamentals in 2025.In the road transportation vehicles business, as tariff policies and the results of anti-dumping and anti-subsidy investigations finalize, coupled with the traditional peak season in the third quarter, the North American semi-trailer business is expected to see a weak recovery; the European semi-trailer business will maintain its resilience amid a “weak recovery” market environment. In 2H 2025, CIMC Vehicles will evolve its “intercontinental operation” into a “borderless enterprise” model, continue to strengthen its strategic presence in Southeast Asia and Africa, and establish regional business groups for the Global South market; domestically, it will continue to focus on new energy, accelerate its transformation to become a “full-value-chain” operator of StarLink semi-trailers, and further increase its market share.II. In the Energy Industries FieldIn the energy, chemical, and liquid food equipment business, shell expects that both demand for and supply of LNG will continue to grow after 2030, with the market share of LNG in total global natural gas demand rising from approximately 14% in 2024 to approximately 25% by 2050, particularly in the Asian market. The International Energy Agency (IEA)’s “Gas Market Report Q3-2025” predicts that global natural gas consumption will reach a record high in 2026, with natural gas demand in Asia in particular projected to grow by over 4% and LNG imports expected to increase by approximately 10%. CIMC Enric will continue to advance the replication and implementation of strategic clean alternative fuel projects, such as coke oven gas to hydrogen co-production LNG and biomass-based green methanol, to cultivate new performance growth points.In the offshore engineering business: The FPSO market shows a high certainty of demand in the short term, underpinned by a substantial reserve of long-term projects. Market demand is forecast to remain robust over the next five years, with major projects centered in South America and Africa and main builders in China and Singapore. In the second half of the year, the Group’s offshore engineering business will firmly advance its strategic vision, concentrating on its established product lines to consolidate competitive advantages and amplify its successes. The three major business lines will continue to break new ground, with offshore oil and gas as the foundation, gradually expanding to new energy sources to form a business portfolio that dilutes the impacts of the industrial cycle.III. In the Finance and Asset Management FieldIn the offshore engineering asset operation and management business of CIMC, in 2H 2025, oil prices are expected to remain volatile and under pressure, influenced by ongoing tariff fluctuations, adjustments in “OPEC+” policies, and geopolitical uncertainties, as forecast by numerous institutions and investment banks. Global oil and gas investment is projected to reflect structural shifts as “increased deepwater investment, diminished shale and counter-cyclical in national oil companies”. Daily rates for mid-to-deepwater offshore drilling platforms are anticipated to remain stable. The Group will adhere to an operating strategy of “maintaining stable operations, promoting asset turnover and expanding market reach”, ensuring the safe and smooth operation of leased assets while proactively securing lease renewals, accelerating the disposal of jack-up and accommodation platform assets, and advancing the marketing of mid-to-deepwater and ultra-deepwater platforms to consolidate its leading position in the global offshore engineering market.About China International Marine Containers (Group) Co., Ltd.The CIMC Group is a world-leading equipment and solution provider in the logistics and energy industries, and its industry cluster mainly covers logistics and energy fields, strengthening its position as a global market leader. In the logistics field, the Group still adheres to taking container manufacturing business as its core business, based on which to develop road transportation vehicles business, airport facilities and logistics equipment/fire safety and rescue equipment business and to a lesser extent, logistics services business and recycled load business providing products and services in professional field of logistics; in the energy field, the Group is principally engaged in energy/chemical/liquid food equipment business and offshore engineering business; meanwhile, the Group also continuously develops emerging industries and has finance and asset management business that serves the Group itself. As a diversified multinational industrial group that shoulders the mission of global serving, CIMC owns a total of 4 listed companies and over 300 member enterprises in Asia, North America, Europe, Australia, and others, and extensive customers and sales networks covering more than 100 countries and regions. In 2024, the Group recorded a revenue of RMB177.664 billion, with gross profit margin remaining at 12.52% and net profit of RMB4.195 billion. The Group was ranked 154th in the Fortune 500 China 2025. For more information, please visit http://www.cimc.com/. For investor relations and media enquiries, please contact LBS Communications Consulting LimitedIR Email: cimcir@lbs-comm.com Joanne ChanTel: (852) 9616 2676Email: jchan@lbs-comm.comJoan YangTel: (86) 176 7074 8753Email: jyang@lbs-comm.com   Copyright 2025 ACN Newswire via SeaPRwire.com.

DUBAI, Aug 26, 2025 - (ACN Newswire via SeaPRwire.com) - BESTCOMP GROUP, a leader in ICT solutions and system integration across the South Caucasus and Central Asia, is proud to partner with 31 Concept (31C), an AI-driven data intelligence innovator focused on network visibility and analytics for telecoms, government, and enterprise clients.Bestcomp Group and 31 Concept Form Strategic PartnershipBESTCOMP, founded in 1995, brings deep experience in turnkey data centers, cybersecurity, networking, cloud services, and software development - backed by over 3,750 completed projects, 10,000+ clients, and more than 500 professional certifications across seven countries. 31 Concept specializes in network intelligence solutions powered by AI - helping clients classify encrypted traffic, optimize performance, and gain real‑time subscriber insights.Under the agreement, Bestcomp will integrate 31 Concept's advanced network intelligence platform into its portfolio across strategic markets. The partnership aims to accelerate digital transformation efforts by combining Bestcomp's strong regional presence with 31 Concept's AI‑powered analytics capabilities."This collaboration brings together Bestcomp's trusted infrastructure expertise and 31 Concept's deep network intelligence. It positions us to deliver smarter, more secure, and more efficient ICT services across the region," said a Bestcomp spokesperson."We're excited to expand our reach via Bestcomp's extensive network and help deliver next‑generation visibility and control to telecoms and enterprises across Eurasia," added a representative from 31 Concept.Key highlights of the partnershipEnhanced visibility and control: 31 Concept's AI‑driven platform offers granular traffic classification, encrypted traffic handling, and real‑time subscriber insights - supporting proactive network optimization.Strategic regional delivery: Bestcomp will deploy these capabilities as part of its managed services, system integration, cloud migration, and cybersecurity offerings throughout the South Caucasus and Central Asia.Joint innovation roadmap: Both firms plan co‑development of tailored solutions for emerging use cases including 5G, secure government networks, and critical infrastructure monitoring.Client impact: Enterprises and service providers in the region will benefit from improved security, performance, and analytics smart enough to meet evolving demands.About Bestcomp GroupEstablished in 1995, Bestcomp Group is a leading ICT service provider in the South Caucasus and Central Asia. It offers a comprehensive suite of solutions - ranging from turnkey data centers and telecom networking to cybersecurity, cloud services, and IT consulting. The company operates across seven countries, with a reputation for quality, innovation, and strong vendor partnerships bestcomp.net.About 31 Concept31 Concept delivers AI‑powered network intelligence to telecom operators, government agencies, and enterprises. Its platform focuses on traffic visibility, encrypted packet classification, and AI‑driven analytics. The company recently revealed a patent‑pending network intelligence technology set to debut at ISS Asia 2025.Contact InformationBestcomp GroupVisit our website at bestcomp.net for media inquiries and partnership details31 ConceptVisit our website at 31c.io for media inquiries and partnership detailsContact InformationMisha HaninCEOmisha.hanin@31c.ioSOURCE: 31 Concept Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 25, 2025 - (ACN Newswire via SeaPRwire.com) - The Payment Cards Group Limited (“PCG”), a cloud-native payment processor and acquirer, continues to advance digital transformation and sustainable development in Hong Kong through innovative payment technologies. In July 2025, PCG and its subsidiaries Yedpay and BBMSL demonstrated their industry leadership at both international and local events by sharing insights on strategic partnerships, showcasing its innovative “SoftPOS” payment solution, and launching promotional offers with PayMe. These efforts help merchants enhance competitiveness and operational efficiency while driving industry transformation and supporting the development of a green economy.Pioneering green payment innovation: Yedpay “SoftPOS” empowers NFC-enabled smart devices as secure payment terminalsOn July 9, 2025, PCG’s digital payment acceptance business, Yedpay, introduced its groundbreaking digital payment solution, “SoftPOS,” at the Low Carbon Living Symposium 2025. Powered by PCG’s innovative technology, “SoftPOS” transforms any NFC-enabled smart device into a secure payment terminal, facilitating a cashless society while reducing hardware waste. Featuring bank-level encryption and PCI DSS compliance, “SoftPOS” delivers transaction security equivalent to traditional terminals while offering superior speed and adaptability. During the event, SUNMI collaborated with Yedpay to demonstrate a practical merchant implementation through integration with their Smart Desktop Terminal. In addition to minimizing hardware requirements, the seamless operations of “SoftPOS” enhances the one-tap payment functionality in the retail and F&B sectors and enables merchants to implement cashless payments within minutes. It also supports green lifestyle reward programs such as GreenCorner, further promoting sustainable consumption and commerce.PCG shares strategic partnership insights at MarTech Summit Hong Kong 2025On July 8, 2025, Andy Leung, former Marketing Director of PCG, spoke at the MarTech Summit Hong Kong 2025, a global marketing technology event. During the panel discussion themed “Collaborative Marketing - Unlocking Growth Through Strategic Partnerships,” he shared how PCG drives payment innovation and creates long-term value for businesses through cross-industry strategic collaboration. He highlighted the critical role of partnerships in enhancing brand competitiveness, building lasting customer relationships, and accelerating industry transformation. During the panel discussion, representatives from Shake Shack, Mox, a digital bank backed by Standard Chartered, and Jebsen Group also shared insights on strategic partnerships from their respective industry perspectives.BBMSL collaborates with PayMe to launch promotions, fostering market expansion for merchantsSince BBMSL, a payment solutions provider under PCG, became a payment acquirer for digital wallet, PayMe by HSBC, last year, the two companies have continued to strengthen their partnership. Recently, BBMSL teamed up with PayMe to launch promotions sponsored by PayMe for merchant partners, More Yogurt and Toys“R”Us:1.Chillout with PayMe! PayMe drink voucher* — Spend HK$30 or more with PayMe at any More Yogurt outlet (excluding Tai Po YATA store) and receive a HK$3 discount on your entire transaction. Offer valid until October 31, 2025.2.Toys“R”Us Instant Discount Offer* — Spend HK$500 or more with PayMe at Toys"R"Us and receive a HK$20 discount on your entire transaction. Offer valid until August 31, 2025.BBMSL aims to leverage these promotions to help merchants drive sales and deepen customer engagement in today’s challenging consumer market, thereby enhancing brand value. Beyond its continued focus on payment innovation, PCG and its subsidiaries are committed to fostering digital transformation and sustainable development across industries through strategic partnerships and data-driven marketing, creating shared success for merchants, consumers, and the environment. *Please refer to the PayMe app for promotion details, terms, and conditions,About Payment Cards Group (“PCG”)The Payment Cards Group Limited (“PCG”) is an innovative and leading payment technology company with operations in Singapore, Hong Kong and the Asia-Pacific region. Established in 2016, PCG has become an acquirer with principal memberships in all major card schemes and e-wallet networks. Yedpay, a member of PCG, has firmly established itself as a digital payment acceptance business in Hong Kong. Meanwhile, A3A, another member of PCG, has developed a cloud-native payment processing platform that operates through RESTful APIs, significantly reducing costs and streamlining complex processes while providing users with real-time transaction data and insights. As an acquiring processor, PCG serves as the backbone infrastructure of the entire payment industry by its Asia’s 1st cloud-based processing and settlement platform. Rooted in Hong Kong with a global vison, PCG seeks to empower merchants with cutting-edge payment technology solutions and drive high-quality development in the global payment ecosystem. For more information, please visit PCG’s website: https://www.yedpay.com/en/For media enquiries, please contact:AJA (IR and Communications)Avy YuTel: (852) 9500 4443Email: avy.yu@ajacapital.com.hk / info@ajacapital.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 25, 2025 - (ACN Newswire via SeaPRwire.com) - Dida Inc. (“Dida” or the “Company”, Stock Code: 02559.HK), a leading technology-driven mobility platform, announced the audited consolidated annual results for the six months ended June 30, 2025.Financial Highlights:- Revenue was RMB 286.3 million for the six months ended June 30, 2025, compared to RMB 404.1 million for the six months ended June 30, 2024.- Gross profit was RMB191.8 million for the six months ended June 30, 2025,compared to RMB 296.1 million for the six months ended June 30, 2024.- Net profit was RMB134.3 million for the six months ended June 30, 2025,compared to RMB 947.9 million for the six months ended June 30, 2024.- Adjusted net profit (non-IFRS measure) increased by 4.7% from RMB129.7 million for the six months ended June 30, 2024 to RMB135.8 million for the six months ended June 30, 2025.Operation Highlights:- Gross transaction value amounted to RMB 2,608 million and total number of orders reached 43.2 million for the six months ended June 30, 2025.- Registered users reached over 395 million as of June 30, 2025.- Certified private car owners reached 19.9 million.- During the first half of 2025, the order volume for our station-based carpooling model increased month by month.Business OutlookCarpooling marketplace businessRiders on our carpooling platform can access low-cost mobility options and enjoy quality experience. Private car owners can save money on gas and tolls by sharing traveling expenseswith riders. Carpooling also brings about numerous societal benefits, such as reducing carbon emissions and mitigating traffic congestion.We believe the primary reason riders choose carpooling is its pricing, while the pain point for car owners is the cost of detours. This year, we continue to focus on optimizing our station-based carpooling model to further reduce detour distances for car owners and fares for riders. During the first half of 2025, the order volume for our station-based carpooling model increased month by month. It is also noteworthy that carpooling travel has distinct route specific characteristics. Unlike ride-hailing service, there is a potential semi-acquaintance relationship between drivers and riders. In the first half of this year, we experimented with enhancing these semi-acquaintance interactions between drivers and riders and achieved positive results.We believe that compared to the current door-to-door pickup model, It is more reasonable for private car owners to pick up passengers with no or minimum detour, while accept riders to pay at a discounted fare. Unlike the transactional nature of ride-hailing services, drivers and riders in carpooling lead to a more equal interaction. They may come from similar social,economic, or geographical backgrounds. In the future, we will continue to explore the unique characteristics of our business to provide users with an affordable, efficient and equitable ride-sharing experience.We will continue to enhance the user experience on our platform. In the second half of the year, we plan to work with ride-hailing platforms to address the needs of those carpooling riders who are not able to find matching private car owners and other on-demand travel needs. We believe this will enhance our platform’s ecosystem and service offerings.Additionally, our platform has attracted nearly 20 million private car owners. This year,we intend to collaborate with partners to provide private car owners with more aftermarket service offerings such as repair and maintenance, financing, insurance and used car trading.Taxi businessIn selected cities where we have already entered into strategic cooperation agreements, we continue to engage with all relevant stakeholders, including local authorities, taxi industry associations, taxi companies, and taxi drivers to implement dynamic pricing solutions.For the full announcement of Dida for the six months ended June 30, 2025, please visit:https://manager.wisdomir.com/files/594/2025/0822/20250822203001_23855082_en.pdfAbout Dida Inc.Dida Inc. (“Dida” or the “Company”, Stock Code: 02559.HK) is a leading technology-driven mobility platform in China. The Company creates more transit capacity with less environmental impact by providing carpooling marketplace services to pair up riders with private car owners if they are heading in similar directions at compatible times. It also provides smart taxi services, aiming to improve the efficacy and efficiency of relevant stakeholders in the taxi industry in China. Dida makes the mobility ecosystem greener and more efficient, and each trip experience warm and enjoyable.Forward-Looking StatementsThis press release contains forward-looking statements relating to the business outlook, forecast business plans and growth strategies of the Company. These forward-looking statements are based on information currently available to the Company and are stated herein on the basis of the outlook at the time of this press release. They are based on certain expectations, assumptions and premises, some of which are subjective or beyond the control. These forward-looking statements may prove to be incorrect and may not be realized in future. Underlying the forward-looking statements is a large number of risks and uncertainties. Further information regarding these risks and uncertainties is included in the other public disclosure documents on the corporate website. Copyright 2025 ACN Newswire via SeaPRwire.com.

Brisbane, Queensland, Australia--(ACN Newswire via SeaPRwire.com - August 21, 2025) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that as a result of strong investor demand, the Company has increased the size of its previously announced "bought deal" public offering (the "Underwritten Offering") from gross proceeds of approximately C$5,000,000 to gross proceeds of approximately C$6,000,000. Pursuant to the upsized Underwritten Offering, Red Cloud Securities Inc. ("Red Cloud"), as sole underwriter and bookrunner, has agreed to purchase for resale 6,666,667 units of the Company (each, a "Unit") at a price of C$0.90 per Unit (the "Offering Price").Each Unit will consist of one common share of the Company (each, a "Unit Share") and one common share purchase warrant (each, a "Warrant"). Each Warrant shall entitle the holder to purchase one common share of the Company (each, a "Warrant Share") at a price of C$1.35 at any time on or before that date which is 36 months after the Closing Date (as herein defined).The Company has granted to the Underwriter an option (the "Over-Allotment Option", and together with the Underwritten Offering, the "Offering"), exercisable, in whole or in part, at any time for a period of up to 30 days after and including the Closing Date, to purchase for resale the number of additional Units equal to up to 15% of the number of Units sold pursuant to the Underwritten Offering at the Offering Price to cover over allotments, if any, and for market stabilization purposes.The net proceeds from the Offering will be used by the Company to fund ongoing operations including, but not limited to, commercial development, product development and working capital. In connection with the Offering, the Company intends to file a prospectus supplement (the "Supplement") to the Company's final short form base shelf prospectus dated March 7, 2025 (the "Shelf Prospectus"), with the securities regulatory authorities in each of the provinces and territories of Canada, except Quebec. The Units may also be sold in the United States on a private placement basis pursuant to one or more exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and in such other jurisdictions outside of Canada and the United States, in each case in accordance with all applicable laws provided that no prospectus, registration statement or similar document is required to be filed in such jurisdiction, and provided the issuance of the Units (including the underlying securities) is permitted under laws applicable to the Company (including the Australian Corporations Act 2001 (Cth).Copies of the Shelf Prospectus and the Supplement to be filed in connection with the Offering, can be found on SEDAR+ at www.sedarplus.ca. The Shelf Prospectus contains, and the Supplement will contain, important detailed information about the Company and the Offering. Prospective investors should read the Supplement, the Shelf Prospectus and the other documents the Company has filed on SEDAR+ at www.sedarplus.ca before making an investment decision.The Offering is expected to close on or about September 3, 2025 (the "Closing Date"), or on such date as agreed upon between the Company and Red Cloud. The closing of the Offering is subject to the Company receiving all necessary regulatory approvals, including the approval of the TSX Venture Exchange to list, on the Closing Date, the common shares of the Company issuable from the sale of Units as well as upon the exercise of the Warrants.This press release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the U.S. Securities Act, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.About GMGGMG is an Australian-based clean-technology company, which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in-house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low-cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy saving coating), which is now being marketed into other applications, including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium ion batteries.GMG's 4 critical business objectives are:Produce Graphene and Improve/Scale Cell Production ProcessesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding the expected size and terms of the Offering, the anticipated timing of closing the Offering, the ability of the Company to satisfy all conditions to closing the Offering, and the expected use of proceeds from the Offering.Such forward-looking statements are based on a number of assumptions of management, including, without limitation, expectations and assumptions concerning the business objectives of the Company; the Company's ability to carry out current planned capital projects, research and development, manufacturing, production, sales and marketing programs for its graphene and graphene-enhanced products and solutions; that the Company will receive the necessary regulatory approvals for the Offering; use the proceeds from the Offering as anticipated; the Company's performance and general business and economic conditions.Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: the risk that the Company is not able to use the proceeds from the Offering as anticipated by management; the risk that the Company does not receive the requisite regulatory approvals for the Offering; overall economic conditions; technical de-risking and market acceptance for the Company's products and solutions; the introduction of competing technologies or products; stock market volatility; environmental and regulatory requirements; competitive pressures; change in market conditions and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied in these forward-looking statements; the volatility of global capital markets; political instability; the failure of the Company to obtain regulatory approvals, attract and retain skilled personnel; unexpected development and production challenges; unanticipated costs and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated October 3, 2024 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws.NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATESTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/263313 Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 21, 2025 - (ACN Newswire via SeaPRwire.com) - Ta Yang Group Holdings Limited (“Ta Yang Group” or the “Group”; Stock Code: 1991), a well-established Hong Kong-listed company with nearly two decades of market presence, plans to further advance comprehensively into the Web 4.0 field and artificial intelligence (AI) industry. The Group will leverage AI Digital Humans as its subsequent growth engine, integrating a Real World Assets (RWA) tokenization operation platform with its inherent global traffic marketing operation system to strategically deploy across three trillion-dollar sectors: education, gaming, and big health.Against the backdrop of AI fueling a new wave of global digitization, AI is evolving from a “technological tool” to the “core of transformation” for many enterprises, driving industries to change work methods, overcome efficiency boundaries, and reshape value paradigms. IDC research indicates that for every dollar invested in generative AI, enterprises can achieve a return on investment of 3.7 times; companies deeply embracing AI have realized an average value return cycle of 13 months. Over 50% of organizations are accelerating customized AI application development, converting short-term gains into long-term competitive advantages. PwC forecasts that by 2030, AI will be a global economic game-changer, contributing up to US$15.7 trillion in growth and adding approximately 26.1% to China’s GDP. It is no surprise that AI Digital Humans, as the core multi-modal interactive carriers across industries, are gradually transitioning from concept to industrial implementation.In 2023, the Group invested in Jusheng Technology Co., Ltd. (“Jusheng Technology”), a professional digital marketing services company. Jusheng Technology plans to launch its independently developed AI Digital Humans, integrating leading technologies such as machine learning, natural language processing (NLP), computer vision (CV), speech synthesis/recognition (TTS/STT), and compatible with the xAI Grok API. This AI Digital Human is at an industry-leading level and will be introduced to three major scenarios: education, gaming, and big health. This includes, but is not limited to: a “Virtual Teacher” AI Digital Human that can adjust speaking speed and learning difficulty in real time based on students’ attention; AI NPCs in games with personalized storylines that evolve based on different player choices; and a “Health Companion” AI Digital Human offering proactive suggestions based on individuals’ 24/7 health data such as heart rate and blood pressure. The Group plans a “phased iterative and gradual open” strategy, expecting to complete the core modules and underlying technology integration within six months, release AI Digital Human prototypes for the three scenarios in the following 6 to 18 months, and integrate these into Jusheng Technology’s marketing matrix. Between 18 and 36 months, the Group aims to open related APIs or SDKs and attract global developers to build an open ecosystem.Additionally, the Group intends to take advantage of this AI and digital transformation opportunity by using blockchain-based RWA to enable off-chain cash flow-generating asset projects to be captured in real time by AI Digital Humans and recorded in smart contracts. The Group will structure and issue layered packages of assets including educational copyrights and gaming IPs tailored to investors’ risk preferences. The target for this type of asset issuance is to pilot 10 high-quality projects in the first year, with plans to expand to 100 projects within three years, involving total asset values of HK$500 million. The Group aims to serve total asset values exceeding HK$5 billion within five years, establishing a multi-domain RWA asset operation platform.It is noteworthy that RWA transactions eliminate the need for traditional brokers or intermediaries, enabling a direct connection between the physical economy and virtual markets. According to Boston Consulting Group estimates, the RWA tokenization market could grow to a valuation of US$16 trillion by 2030, underscoring its vast market potential and promising outlook.Leveraging Jusheng Technology’s 20 years of cross-border marketing experience, Ta Yang will build a traffic system characterized by “comprehensive coverage + intelligent operation + scalable growth.” Jusheng Technology’s platforms cover overseas social media such as TikTok, Instagram, Facebook, as well as domestic channels like Douyin and WeChat Video Accounts, facilitating global user reach for customers. Utilizing AI technology, processes such as account nurturing, content generation, and targeted delivery will be fully automated to reduce operational costs and improve customer acquisition efficiency. Based on this, Ta Yang Group has a clear user growth target: to attract 1 million users in the first year to form an initial traffic pool, reach over 10 million users within three years, and build a native Web 4.0 traffic pool of hundreds of millions of users within five years, creating a “traffic – conversion – repurchase” cycle.Ms. Shi Qi, Chairlady of Ta Yang Group, stated, “Ta Yang is unveiling its AI transformation blueprint and formally entering the digital asset arena, marking a significant milestone for the Group and opening a new chapter for future development. We are grateful for investors’ recognition and confidence in our growth. As a well-established Hong Kong-listed company with nearly two decades of market history, this entry into the AI industry is expected to generate four types of revenue: income from AI Digital Human-driven traffic; revenue from providing AI+RWA one-stop financing consultancy services to SMEs; matchmaking fees related to RWA transactions, as well as digital advisory subscription fees; and multilingual, multicultural AI customer service and marketing outsourcing fees charged on a per-project or annual basis. Benefiting from its business model, Jusheng Technology has maintained positive cash flow in recent years, providing ample resources for this broader AI and digital transformation initiative. As the Group’s vision through Jusheng Technology in AI gradually materializes, we look forward to creating greater value and delivering promising returns for our shareholders.”About Ta Yang Group Holdings Limited (SEHK: 1991.HK)Ta Yang Group Holdings Limited (Stock Code: 1991) was established in 1991 and successfully listed on The Stock Exchange of Hong Kong Limited in 2007. It is a diversified enterprise combining three decades of industry experience with a forward-looking digital vision. Since its founding, the Group initially focused on the field of silicone input devices, specializing in the design and manufacture of core components used in consumer electronic devices, computers, laptops, mobile phones, and automotive peripherals. Leveraging a highly integrated production system, stringent quality control, and technological innovation capabilities, the Group has earned long-term trust from numerous globally renowned brand clients, laying a solid industrial foundation.With the deepening wave of global digital transformation, Ta Yang Group has keenly identified strategic opportunities in the digital economy era and decisively launched a comprehensive strategic transformation toward the Web 4.0 domain. Centered on “embracing technological change and reshaping the value ecosystem,” the Group precisely anchors on three core drivers: artificial intelligence (AI), Real World Assets (RWA) tokenization, and Hong Kong’s policy ecosystem. It is dedicated to bridging the transformation chain of “data — assets — value,” marking its leap from a traditional manufacturing enterprise to a digital economy pioneer.Currently, Ta Yang Group regards its Web 4.0 strategic transformation as a new starting point, focusing on the three trillion-dollar sectors of education, gaming, and big health. It aims to become a leading enterprise in the Asia-Pacific region across the dual arenas of AI and RWA, providing efficient value growth ecosystems for global investors, partners, and individual users. The Group is committed to continuously advancing high-quality development of the global digital economy and writing a new chapter from being an “industry deep cultivator” to a “digital ecosystem builder.” Copyright 2025 ACN Newswire via SeaPRwire.com.

2025 Interim Results Highlights- Total revenue increased by 9.40% YoY to approximately NTD585.31 million- Gross profit increased by 28.98% YoY to approximately NTD201.97 million- Overall gross profit margin rose by 5.24 percentage points to approximately 34.51%- Total comprehensive income attributable to owners of the Company for the period increased significantly by118.02% YoY to approximately NTD68.24 million- Revenue from turnkey solutions reached approximately NTD113.69 million- Basic earnings per share increased by 25.84% YoY to approximately NTD4.87 centsHONG KONG, Aug 21, 2025 - (ACN Newswire via SeaPRwire.com) - Genes Tech Group Holdings Co. Ltd (“Genes Tech Group” or “The Group”, Stock Code: 8257.HK) announces its interim results for the six months ended 30 June, 2025 (“During the period”). During the period, the Group’s performance demonstrated steady growth. The total revenue of the Group reached approximately NTD585.31 million, representing a year-on- year (“YoY”) increase of 9.40%. Total comprehensive income attributable to owners of the Company for the period amounted to approximately NTD68.24 million, representing a significant YoY increase of 118.02%. Basic earnings per share were approximately NTD4.87 cents, representing a YoY increase of 25.84%.During the period, revenue from turnkey solutions amounted to approximately NTD113.69 million, accounting for approximately 19.42% of the Group’s total revenue. The revenue from trading of parts and used SME amounted to approximately NTD471.62 million, accounting for approximately 80.58% of the Group’s total revenue. The Group adheres to its core strategy of prudence and stability, striving to strengthen the stability and continuity of cooperation with existing international clients while actively expanding new clientele to diversify risks. During the period, the Group’s revenue from operations in the United States increased significantly by 78.54% from last year, accounting for approximately 38.68% of the total revenue of the Group, while revenue from operations in Taiwan increased by 48.97% from last year, accounting for approximately 49.69% of the total revenue the Group.In the first half of 2025, the global semiconductor market continued its growth momentum. Driven by new technologies such as AI, the penetration rates of new technologies and products in areas such as automotive electronics, new energy, the Internet of Things, big data and artificial intelligence continued to rise. Furthermore, the deepening development of cutting-edge technologies such as “AI+” and “5G+”, along with the rapid growth in demand for AI computing power, have become key drivers of semiconductor demand, creating a favorable development environment for semiconductor companies. According to the latest report from the Semiconductor Industry Association (SIA), global semiconductor sales reached USD59 billion in May 2025, up 19.8% from USD49.2 billion in May 2024, marking 19 consecutive months of year-on-year growth and a 3.5% increase from the previous month. The growth in the global chip market was primarily driven by strong demand from the Americas and Asia- Pacific regions.Mr. Yang Ming-Hsiang, Chairman and Chief Executive Officer concluded: “Driven by the strong momentum of AI technology, the semiconductor industry is entering a period of rapid growth in economic profits. However, amidst the current volatile international landscape, the semiconductor industry faces challenges in supply chain stability. The Group will assess the situation, pursue progress while maintaining stability, and continuously enhance its core value and competitiveness to create sustainable long-term investment returns for shareholders.”About Genes Tech Group Holdings Co. Ltd (Stock Code: 8257.HK)Genes Tech Group Holdings Co. Ltd is a turnkey solution provider and exporter of parts and used SME in Taiwan. Since the commencement of its business in 2009, the Group mainly engaged in providing turnkey solution for parts and used SME for its customers and modifying and/or upgrading the semiconductor equipment of its production systems according to customers needs. In addition, the Group is also engaged in the trading of SEM and parts. The SME and parts supplied by the Group included furnaces, clean tracks and other related items, which were used at the front-end of the semiconductor manufacturing process, wafer fabrication such as deposition, photoresist coating and development, and these were extensively applied in mobile phones, game consoles, DVD players, automotive sensors and other digital electronic products.The press release is distributed by Vitalink Consultants Limited on behalf of Genes Tech Group Holdings Co. Ltd. For enquiry, please contact:Ms. Natural Lau  Tel: (852) 2529 7999  Email: Natural.lau@vitalink.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 22, 2025 - (ACN Newswire via SeaPRwire.com) - Everbright Grand China Assets Limited ("Everbright Grand China" or the "Group"; HKEX stock code: 03699.HK), a subsidiary of China Everbright Group, principally engaged in the businesses of property leasing, property management and the sales of properties held for sale, announced its interim results for the six months ended 30 June 2025 ("Reporting Period").During the Reporting Period, revenue of the Group was approximately RMB24.5 million,  representing an increase of approximately RMB0.6 million as compared with 2024. Profit attributable to equity shareholders was approximately RMB10.1 million, representing a decrease of approximately RMB1.3 million as compared with 2024, mainly attributable to the increase in the PRC income tax and deferred taxation. Gross profit was approximately RMB18.1 million, representing an increase of approximately RMB0.6 million as compared with 2024. Basic earnings per share of the Group was approximately RMB2.30 cents (2024: RMB2.59 cents). The Board declared an interim dividend of RMB0.73 cents (equivalent to HK0.80 cents) per ordinary share.Considering that the current operating environment remains relatively challenging, the Board declared an interim dividend of RMB0.73 cents (equivalent to HK0.80 cents) per ordinary share, as a token of appreciation to shareholders for their continuous support. In the second half of the year, the Company will decide on dividend distribution taking into account factors such as business development needs, financial performance and capital position, as well as performance growth, in order to bring the best return to the Company's shareholders and investors.In 2025, global economic environment continues to be characterized by uncertainties. Factors such as geopolitical risks, inflationary pressures and monetary policy adjustments in major economies around the world continue to affect market confidence and capital flows. Nevertheless, the overall stability of China’s economy, the gradual rebound of the consumer market and the continued optimization and upgrading of the industrial structure have provided a solid foundation for the development of the property management and leasing industry.For the six months ended 30 June 2025, the Group generated rental income of approximately RMB17.0 million (2024: RMB16.3 million), representing an increase of approximately RMB0.7 million as compared to the same period last year. The Company’s properties maintained an occupancy rate of approximately 81%, with the overall leasing market performing solidly, although newly signed rents declined compared to the previous period. In the face of downward pressure on rents, the Group will enhance its consolidated earning power by adding additional services to new leases to mitigate the impact of lower rents on overall revenue. This not only enriches the service offerings, but also helps to enhance customer stickiness and satisfaction, further consolidating the Group’s market competitiveness.During the period, revenue from the property management services was approximately RMB7.5 million (2024: RMB7.6 million), representing a decrease of approximately RMB0.1 million as compared to the same period last year. In terms of property portfolio strategy, the Group actively promotes tenant diversification to mitigate industry risks and adapt to the accelerated rise and fall of market environment of various industries. The Group’s existing properties are mainly concentrated in two core cities of Chengdu in Sichuan Province and Kunming in Yunnan Province, covering three commercial buildings, namely Everbright Financial Center, Everbright International Mansion and Ming Chang Building, with a total gross floor area of approximately 89,507 square meters. Benefiting from its excellent geographical location and sound property quality, it has attracted a large number of state-owned enterprises and large organizations to move in and has a solid leasing base. In the future, the Group will promote business diversification to enhance its overall risk-resistant capability.In terms of overseas investment, the Group is evaluating investment opportunities in international markets and is cautiously optimistic about overseas markets. Notwithstanding the volatility of the global economy, the Group will adhere to the principle of prudence and flexibility in its investment horizon to ensure the safety and profitability of its capital operations.As at 30 June 2025, The Group maintained cash and bank balances and bank deposits of approximately RMB236.2 million (31 December 2024: RMB231.5 million). The Group’s gearing ratio, being measured by the Group’s total liabilities over its total assets, was 18.6% (31 December 2024: 18.0%). The Group’s liquidity position was well-managed.Looking ahead to the second half of 2025, there are no new property management projects for the time being, despite favourable lease performance in the first half of the year. The Group is actively looking for suitable investment windows for its acquisition and investment plans which were delayed during the epidemic. With the active domestic economy and falling interest rates, the market’s willingness to invest has increased significantly.The Group will continue to deepen its digital transformation and actively utilize technology to promote the construction of intelligent properties and enhance operational efficiency and customer experience. Through technological empowerment, we optimize the allocation of human resources and service processes, enhance the level of intelligence and refinement of property management, and improve overall service quality and customer satisfaction.In addition, the Group will fully utilize the synergies with its parent company, China Everbright Group, and leverage on the popularity of the “Everbright” brand and its resource advantages to actively develop diversified value-added services, enrich its revenue structure and enhance its brand influence. In the face of industry restructuring and upgrading, the Group insists on stable operation, focuses on risk management and internal control, responds flexibly to changes in the macro-economy and policies, and continues to optimize its asset portfolio in order to enhance its risk-resistant capability. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 21, 2025 - (ACN Newswire via SeaPRwire.com) - Focusing on the field of tumor treatment, innovative biopharmaceutical company Lepu Biopharma Co., Ltd. (Lepu Biopharma or the Company, stock code: 2157.HK) announced its interim results for the first half of 2025. During the reporting period, the Company's business showed strong growth momentum, achieving profitability for the first time. Core product sales and international licensing business progressed in tandem, with multiple ADC pipeline products entering key clinical stages and global commercialization efforts accelerating.Lepu Biopharma is an innovation-driven biopharmaceutical company focusing on oncology therapeutics, in particular, targeted therapy and oncology immunotherapy, with a strong China foundation and global vision. Lepu Biopharma is dedicated to developing innovative ADCs through our comprehensive and advanced ADC technology development platform and we aim to develop optimal and innovative drugs to better serve the unmet medical needs of cancer patients. The Company is committed to continuously developing a market-differentiating pipeline by fully integrating independent innovation capabilities and strategic collaborations. The Company has established and is progressively expanding our internal manufacturing capabilities, driven by the business needs stemming from the upcoming commercialization of our ADC candidates.Currently, Lepu Biopharma has strategically designed our pipeline with a range of oncology products. For clinical-stage candidates, the Company has one clinical/commercialization-stage drug candidate; nine clinical-stage drug candidates, including one co-developed through a joint venture; and three clinical-stage combination therapies of our candidates. One of our drug candidates has obtained marketing approval with respect to two of its targeted indications, with clinical trials for other indications ongoing. Among the nine clinical-stage drug candidates, seven are targeted therapeutics and two are immunotherapeutics, which are an oncolytic virus drug and T cell agonistic antibody.As of the end of the reporting period, Lepu Biopharma has achieved significant milestones in the monetisation of our R&D capabilities through commercialization and BD activities: PUYOUHENG (Pucotenlimab Injection) has completed the full commercialization process and is currently under a rapid sales growth, and four other products, CMG901, MRG007 and two pre-clinical TCE assets have also been licensed out through our BD activities. Notably, CMG901’s global rights have been licensed to AstraZeneca, and MRG007’s rights for regions outside Greater China have been licensed to ArriVent. Two pre-clinical TCE assets have entered into a collaboration with Excalipoint.Revenue scale achieved a 3.5-fold leapfrog growth, with comprehensive improvement in financial indicatorsIn the first half of 2025, the Company made significant progress in advancing its product pipeline and business operations, recording a total revenue of approximately RMB466 million, which was an increase of 350% of the same period in 2024 at RMB133 million. For licensing activities, the Company has recognized approximately RMB309 million in revenue primarily from the out-licensing of MRG007. The Company recorded a revenue of approximately RMB151 million for the sales of PUYOUHENG (Pucotenlimab Injection), marking a significant increase of 58.8% from the sales recorded in the same period in 2024. In addition, the Group recognized approximately RMB6.3 million in revenue for the provision of CDMO services.During the reporting period, the Company achieved profitability for the first time, with a profit of approximately RMB 29.3 million, marking a turnaround from a loss in the same period of 2024. Net cash generated from operating activities was approximately RMB 46.7 million, and cash and cash equivalents increased to approximately RMB 473 million, representing a positive net operating cash flow compared to the same period in 2024. Research and development expenses amounted to approximately RMB 202 million, representing a decrease of 6.6% compared to the same period in 2024. While ensuring the advancement of core pipelines, cost control measures have shown tangible results.The Company actively develops cooperative relationships with various business channel partners. As of June 30, 2025, the Company completed the tendering process on the procurement platform in 28 provinces of the PRC. We have covered approximately 118 cities in the PRC through various sales channels, and we will further expand our sales network.ADC pipeline enters the critical phase with multiple products, potential for combination therapy highlighted, and fruitful international licensing resultsIn the first half of 2025, the Company remained focused on the research and development of its drug candidates, while continuously assessing market demand and competitive landscape relating to the range of oncology therapeutics and the broad spectrum of indications covered by its drug candidates, in order to maximize the competitiveness of its products pipeline. In particular, MRG003 for NPC nears approval and other key drug candidates advance to pivotal clinical stage.MRG003（EGFR-ADCNPC: MRG003 is under NDA review for the treatment of R/M NPC and has also been granted priority review by the CDE of NMPA. The authority is currently proceeding with the clinical and pharmaceutical evaluation of MRG003. The encouraging data of the pivotal Phase IIb clinical study for the treatment of R/M NPC was read out as “late breaking abstract (LBA)” for oral presentation at the ASCO Congress 2025. The Company is also currently conducting the Phase III clinical trial of combination therapy with MRG003 and pucotenlimab on R/M NPC. The encouraging data in phase II clinical trial of combination therapy on R/M NPC will be presented at the ESMO Congress 2025.HNSCC: As of June 30, 2025, the Company is conducting a randomized, open-label, multicenter Phase III clinical study on HNSCC. In terms of combination therapy with MRG003 and pucotenlimab, we are currently conducting the Phase II clinical trial on HNSCC, and the encouraging data in phase II clinical trial will be presented at the ESMO Congress 2025. The  European Medicines Agency (EMA) granted Clinical Trial Authorization (CTA) approvals for the Phase II clinical trial targeting LA-SCCHN in June 2025, and the Company will initiate the clinical trial in the second half of 2025.MRG004A (TF-ADC): The Company has completed the Phase I clinical study on solid tumors in China and the encouraging Phase Ib expansion data on PC will be presented at the ESMO Congress 2025. Protocol communication with CDE for the pivotal clinical trial of MRG004A has been completed, and we have entered the Phase III clinical trial stage in August 2025. In addition, MRG004A was granted BTD by the CDE in August 2025, which offers a brand-new treatment option to patients with pancreatic cancer.MRG006A (GPC3-ADC): MRG006A is a GPC3-targeted ADC with FIC potential globally. We received IND clearance from the FDA in January 2025. We are currently advancing Phase I clinical trial in China. In pre-clinical studies, MRG006A resulted in a robust and dose-dependent tumor growth inhibition on multiple CDX models and HCC PDX models. In the meantime, MRG006A also demonstrated good tolerability in the exploratory toxicology study.MRG007 (CDH17-ADC): We received the IND approval from the NMPA in June 2025 and are currently conducting a Phase Ia clinical trial for the treatment of unresectable locally advanced or metastatic solid tumors. MRG007 has shown robust antitumor activity in preclinical models of GI cancers and a favorable therapeutic index based on IND enabling studies. The pre-clinical data of MRG007 was presented at the AACR Annual Meeting in April 2025. In January 2025, the Company entered into an exclusive licensing agreement with ArriVent, pursuant to which the Company has granted ArriVent exclusive rights to develop, manufacture and commercialize MRG007 outside of Greater China. Under the terms of the agreement, the Company is eligible to receive up to US$1.2 billion in total in upfront payment and development, regulatory and sales milestones, together with tiered royalties on net sales. As of June 30, 2025, the upfront payment has been received.CG0070 (Oncolytic virus): CG0070 was granted BTD by the CDE in January 2025. CG0070 is currently in a MRCT Phase III clinical study conducted by the Company’s U.S. partner, CG Oncology. The latest encouraging data observed has been orally presented in the 120th American Urological Association Annual Meeting in April 2025. The Company has completed the Phase I clinical trial in China and are currently engaged in protocol communication with the CDE regarding the domestic bridging pivotal linical trial.Combination therapy layout: As of June 30, 2025, the Company has completed the Phase II trial of combination therapy with MRG002 and pucotenlimab in the treatment of HER2-expressing solid tumors, which has moved to first-line treatment, and protocol communication for phase III clinical trial has been completed. The Company has observed encouraging data on UC. In terms of combination therapy with MRG003 and pucotenlimab, the Company is currently conducting the Phase II clinical trial on HNSCC, which has moved to first-line treatment, and the encouraging data in phase II clinical trial will be presented at the ESMO Congress 2025. The European Medicines Agency (EMA) granted Clinical Trial Authorization (CTA) approvals for the Phase II clinical trial targeting LA-SCCHN in June 2025, and we will initiate the clinical trial in the second half of 2025, which has been moved up to first-line treatment for advanced disease.Preclinical: Laying the groundwork for innovative platforms and innovative targetsThe Company continuously strives to build up and develop novel technology platforms as innovative engines for the Company. The Company has developed multiple innovative linker-payload platforms for ADC drug candidates, including the Hi-TOPi ADC platform and other early-stage platforms. During the reporting period, our innovative ADC platforms have achieved significant progress. Based on these innovation platforms, the Company has generated two ADC candidates, which are MRG006A with global first-in-class potential and MRG007 with global best-in-class potential, all of which have shown encouraging pre-clinical data and received IND approvals in China. Pre-clinical data of MRG007 was presented at the AACR Annual Meeting in April 2025.On August 1, 2025, the Company entered into a licensing transaction for the license-out and/or transfer of certain intellectual property rights relating to two preclinical assets developed by the Company’s proprietary T cell engager-TOPAbody platform with Excalipoint through entering into the Intellectual Property Assignment and License Agreement.The Company shall receive (i) an upfront payment in cash of US$10 million in aggregate, development and commercial milestone payments in cash of up to US$847.5 million in aggregate and sales royalties, holding a 10% interest, marking international recognition of the platform's value.Future Outlook: Accelerating the Commercialization of Core Products and Advancing Global Strategic DevelopmentIn respect of drug R&D, the Company will further focus on advancing strategic research and development priorities in next generation ADC drugs and IO bi/tri specific antibodies, while accelerating the commercialization of late-stage products. For our registrational stage product MRG003, the relevant authority is currently proceeding with the clinical and pharmaceutical evaluation in an orderly manner. The Company will concentrate our resources and endeavour to expedite the approval process. Meanwhile, our other key drug candidates are entering pivotal clinical stages. Protocol communication for the pivotal clinical trial of MRG004A has been completed, and we have entered the Phase III clinical trial stage in August 2025. In addition, we are currently conducting protocol communication with the CDE regarding the domestic pivotal clinical trial of CG0070. The Company will also explore further potential clinical value of our other innovative drug candidates, such as MRG006A and MRG007. Concurrently, the potential efficacy of combination therapies within our pipeline is being continuously explored, with greater clinical benefits striving to be delivered to a broader patient population.In terms of domestic commercialization, the Company will take further actions to enhance the market accessibility of PUYOUHENG (Pucotenlimab Injection), accelerating market penetration at all levels to further increase market share and enhance the Company's brand image and market recognition. At the same time, the Company will commence the preparation process for the commercial launch of MRG003 and continue to expand our marketing and commercialization teams.On the international front, the Company will ramp up our efforts to expand into the global market. We will expand our international network and explore new business development cooperation opportunities. The Company will remain committed to seeking more strategic partners worldwide to develop our ADC products and other innovative candidates through partnerships, licensing agreements, or joint ventures. Copyright 2025 ACN Newswire via SeaPRwire.com.